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ABSTRACT 
Ruth Link-Gelles: Are we studying who we think we’re studying? Role of socioeconomic status in the 
validity of estimates of pneumococcal conjugate vaccine effectiveness in the United States 
(Under the direction of Daniel Westreich) 
 
Thirteen-valent pneumococcal conjugate vaccine (PCV13) was licensed for use in children in the 
United States in February 2010. Shortly thereafter the Centers for Disease Control and Prevention began 
a post-licensure vaccine effectiveness (VE) study in 13 surveillance sites around the US. Cases were 
identified through active surveillance and controls were matched to cases by age (+/- 14 days) and zip 
code, which was used as a proxy for socioeconomic status (SES).  
Due to issues locating and enrolled cases and controls in an era of increased cell phone usage, 
investigators were concerned that zip code may not provide adequate control for SES and that enrolled 
children may not be representative of eligible children, threatening both the internal and external 
validity of study results.  
We obtained data on SES for cases and controls from a parent interview, birth certificates, and 
via geocoding and linkage to the US Census Bureau’s American Community Survey. We used conditional 
logistic regression models to estimate the adjusted and unadjusted VE and to assess effect measure 
modification by SES of the estimated VE.  
Small differences were found between enrolled cases and enrolled controls; however, these 
differences did not meaningfully change our estimated VE and we therefore concluded that internal 
validity of our estimates was high. Similarly, small differences were found between enrolled and 
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unenrolled cases, but we did not find effect measure modification, indicating that external validity of 
our estimates was high. 
 In addition to providing reassurance that previously published VE estimates are valid, we show 
that, despite not being able to contact unenrolled children, an assessment of validity of observational 
data is feasible.
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To my mom, whose response is always “you can do it.” 
Thank you for reminding me of that over and over again.
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 SPECIFIC AIMS 
In the past decade, many vaccines approved for children in the United States1-4 have been licensed on 
the basis of observational immunogenicity and safety data, rather than on the basis of randomized 
controlled trials (RCT) of vaccine efficacy. In such cases, post-licensure observational studies of vaccine 
effectiveness (VE) are often the only opportunity to evaluate whether a vaccine is working as expected. 
While RCTs estimate vaccine efficacy under carefully controlled use and administration and typically 
have high internal validity, they are often subject to problems with generalizability to the broader 
population (external validity).5 Post-licensure observational studies, however, provide the opportunity 
to assess VE under typical use in the general population (increased external validity), while issues of 
confounding are of greater concern than in RCTs (decreased internal validity). 
 One of the most common types of observational VE study designs is the case-control study, with 
cases identified through active surveillance, and with retrospective ascertainment of vaccination status 
for both cases and healthy controls. In order to increase statistical efficiency when the disease outcome 
under study is rare (as is the case for most vaccine preventable diseases), controls are frequently 
matched to cases based on factors which are likely to confound the relationship between vaccination 
and disease, age being the most common matching factor. While the ideal case-control VE study would 
enroll 100% of cases and a random sample of the target population as controls, this is often not feasible. 
Requirements such as interviewing participants to obtain behavioral risk factors and vaccine histories 
can result in study populations that differ from target populations. If differences between the study 
population and the target population include factors which modify the effect of vaccine on disease, 
external validity is reduced.6  
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 Socioeconomic status (SES), generally measured as a combination of income, education, and 
occupation, is likely to be related to whether or not an individual is located and enrolled in an 
observational study.7,8 Because less affluent individuals may move or change telephone numbers more 
frequently, they may be harder to find than more affluent individuals. Less affluent individuals may have 
less access to or trust in the medical system, and may not be fluent in English, all factors which decrease 
their likelihood of consenting to participate in a study.9-11 At the same time, SES is also an increasingly 
recognized risk factor for many vaccine preventable diseases since it changes exposure patterns, 
increases stress, and decreases access to care;12-17 as such, it may be an effect measure modifier of the 
impact of vaccine on the disease. Therefore, generalizability with respect to SES may be reduced. 
In addition to being a risk factor for both selection into a study and disease outcome status, SES 
is also associated with vaccination status,18-22 meaning that SES may confound the vaccine/disease 
relationship. To deal with such potential confounding, studies often match cases to controls on 
neighborhood (using zip code in the US), a common proxy for SES.23,24 Little research to date has focused 
on understanding how SES may reduce generalizability and/or confound the relationship between 
vaccination and disease, and whether matching on zip code (or other neighborhood indicators) 
eliminates this confounding. 
We propose to use data from a VE study of 13-valent pneumococcal conjugate vaccine (PCV13) 
in the US25 to assess how SES may affect both the internal and external validity of case-control studies of 
VE. Using these data, we will evaluate the internal and external validity of the estimate of VE from this 
study in two separate aims. Specifically, we will: 
 
Aim 1. Evaluate whether zip code matching results in a similar distribution of SES in cases and 
controls; estimate the amount of residual confounding and appropriately adjust the main VE 
estimate. 
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Hypothesis: Although matching by zip code likely controls for some confounding by SES, we expect 
individual (as measured on the birth certificate) and neighborhood (as measured by census tract) level 
SES indicators to differ between enrolled cases and controls, indicating the potential for residual 
confounding. We hypothesize this residual confounding to meaningfully change the VE estimate, which 
for purposes of this analysis will be a 5% absolute change in the estimated VE. 
Aim 2. Assess generalizability in a population-based case-control study by: 
(a) assessing whether enrollment rates differ with respect to SES, and 
(b) determining whether SES is an effect measure modifier of the estimated vaccine 
effectiveness. 
Hypothesis: Enrolled cases will differ substantially from the target population by important 
characteristics, including maternal race/ethnicity, crowding in the household, and prenatal care quality, 
all markers of SES. Additionally, because SES is related to immune system status (through nutrition, 
stress, comorbidities, etc.) and increased risk factors for IPD (e.g., crowding, smoking exposure),26 effect 
measure modification by SES, and therefore reduced generalizability, is likely. 
Together these aims will help improve both the internal and external validity of future VE studies for 
IPD, with potential applications to other VE studies.
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 BACKGROUND AND SIGNIFICANCE 
Role of vaccines and vaccine effectiveness evaluations on public health 
Impact of vaccines on public health 
In 1999, the Centers for Disease Control and Prevention listed universally recommended 
vaccines for children as one of the top ten achievements in public health of the past century.27 Of the 10 
diseases for which universal vaccination was recommended at some point in the 20th century, cases in 
the United States have declined by 96-100% since introduction.28 Smallpox has been eradicated and 
polio is near eradication.29  
Vaccines were again highlighted as a top achievement in 2011, when CDC estimated that 
vaccination of each US birth cohort under the current schedule prevents approximately 42,000 deaths 
and 20 million cases of disease, with corresponding cost savings in the tens of billions.29 Worldwide, 
vaccines were estimated to have prevented 2.5 million deaths in children under age five in between 
2001-2010.30 
Path to vaccine licensure in the US 
Development and licensure of new vaccines in the US is a lengthy process, often lasting a 
decade or more.31 The first step toward licensure is a Phase I trial of the vaccine to evaluate safety. 
These trials are generally extremely small and do not attempt to make conclusions about the efficacy or 
effectiveness. Phase II clinical trials include a few hundred to a few thousands participants and aim to 
evaluate immunogenicity, efficacy, and safety. Finally, for products showing efficacy, but lacking severe 
adverse events, Phase III trials are conducted. These trials can include up to tens of thousands of 
individuals and are the last step before the manufacturer files a Biologic License Application (BLA) with 
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the Food and Drug Administration (FDA).31 The BLA is then reviewed by the FDA and may be presented 
to the Vaccines and Related Biological Products Advisory Committee if data on safety, efficacy, and 
appropriate use need review. During this process the manufacturer works with the FDA to refine the 
indications for use and other statements that will be included in the package insert at the time of 
licensure. Post-licensure changes in the package insert can result from additional human trials or safety 
concerns.31  
After licensure, CDC’s Advisory Committee on Immunization Practices (ACIP) reviews the 
available data and makes recommendations for the actual use of the vaccine in the US. Usually, these 
recommendations mirror those in the package insert approved by FDA, however, ACIP can make “off 
label” recommendations.32 Recommendations are formally issued through CDC’s Morbidity and 
Mortality Weekly Report. 
Importance of post-licensure evaluations for estimating the impact of vaccines 
Once a vaccine is introduced, post-licensure monitoring of safety, impact and effectiveness begin. 
FDA and CDC maintain the Vaccine Adverse Events Reporting System (VAERS) for tracking safety. CDC 
also generally tracks impact and effectiveness through active and passive surveillance and observational 
vaccine effectiveness (VE) studies. Post-licensure VE studies have become increasingly important as new 
vaccines are licensed to replace existing vaccines and it becomes unethical to conduct long-term pre-
licensure studies when a recommended vaccine is already in use.  
Such observational studies have a number of strengths over pre-licensure studies. First, they 
assess real-world effectiveness (i.e., few exclusion criteria, administration of doses on altered or delayed 
schedules, herd protection), rather than the controlled environment of an RCT.33 Second, they 
sometimes help identify groups where the ACIP recommendations are not being fully implemented, and 
can also identify vaccine failures.34,35 Third, post-licensure studies allow estimate of direct and indirect 
benefits,36 whereas traditional, individually randomized controlled trials only allow estimation of direct 
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benefits.37 Limitations of post-licensure observational studies compared to pre-licensure RCTs include a 
potential for uncontrolled confounding, issues with selection bias, and misclassification of exposure 
(vaccination status). 
 Most post-licensure VE studies conducted in the US are population-based, nested case-control 
studies, often with matching to efficiently control for confounding by age and other factors.38-40 Since 
2000, CDC has repeatedly conducted post-licensure VE studies for vaccines against influenza,41 
pneumococcal disease,42 and meningococcal disease43 within defined geographic active-surveillance 
areas. Other groups have used individuals in health maintenance organizations as the target population, 
especially for influenza studies.44  In both cases matching on zip code is a common way to attempt to 
control for confounding by socioeconomic status.42-44 This study design, in turn, has been replicated 
around the world with neighborhood, rather than zip code, matching.45-49 Studying the validity of these 
methods is the focus of the present work. 
Pneumococcal disease and vaccine in the US 
The burden of pneumococcal disease in the pre-conjugate vaccine era 
Streptococcus pneumoniae (pneumococcus) is a major cause of morbidity and mortality 
worldwide. Prior to the development and introduction of 7-valent pneumococcal conjugate vaccine 
(PCV7) in the early 2000s, pneumococcus was the leading cause of pneumonia, bacteremia, sinusitis, 
and acute otitis media worldwide, and also a major cause of bacterial meningitis.2 The World Health 
Organization (WHO) estimates that in 2000, pneumococcus caused 14.5 million cases and 735,000 
deaths in HIV-negative children under the age of five, 7% of all-cause mortality in this age group.50 In 
1999, the year before PCV7 was introduced in the United States, the Centers for Disease Control and 
Prevention (CDC) estimates there were 64,000 cases (23.63/100,000 persons) and 7,300 deaths in all 
age groups in the United States.51 
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Licensure, introduction and effectiveness of PCV7 in the US 
PCV7 (Prevnar™, Wyeth Lederle) was licensed by the US Food and Drug Administration in 
February 2000 and covers the seven serotypes that accounted for approximately 80% of invasive 
pneumococcal infections in the United States in children under six in the pre-vaccine era: 4, 6B, 9V, 18C, 
14, 19F, and 23F. Licensure of PCV7 was based primarily on a prospective double-blind randomized 
controlled trial (RCT) among 37,830 healthy children in a large health maintenance organization in 
California.52 The trial showed PCV7 efficacy against IPD caused by one of the seven serotypes included in 
the vaccine was 93.9% (95% Confidence Interval [CI]: 79.6-98.5%) for one or more doses and 97.4% (95% 
CI: 82.7-99.9%) for the full, four dose, schedule.2,52 Additionally, the study found that children who 
received at least one dose of PCV7 had fewer episodes of less-specific outcomes such as all-cause 
pneumonia and acute otitis media.2,52  
Other factors considered during licensure of PCV7 were double-blind RCTs of a similarly-
formulated 9-valent pneumococcal vaccine among toddlers attending day care in Israel and infants in 
Soweto, South Africa, as well as immunogenicity and safety data from.2,53-61 Both the Israeli and South 
African studies found significant declines in nasopharyngeal carriage of vaccine-included serotypes in 
children who received vaccine compared with children who received placebo (or a non-pneumococcal 
vaccine).53,55  
In the spring of 2000, CDC’s Advisory Committee on Immunization Practices (ACIP) 
recommended PCV7 for routine use in the infant immunization series on a “3+1” schedule, that is a 
three-dose primary series at two, four, and six months of age, with a booster recommended between 12 
and 15 months of age. For children aged 24-59 months with specific underlying conditions, ACIP 
recommended two doses of PCV7, followed at least two months later by a dose of the older 23-valent 
pneumococcal polysaccharide vaccine (PPSV23) which, while not efficacious against otitis media or non-
bacteremic pneumonia, covers a broader range of serotypes (Appendix 1).2  
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From January 1, 2001 through May 31, 2004 CDC conducted a matched case-control study to 
estimate the effectiveness of PCV7 in the United States in children under five years of age.42 One or 
more doses of PCV7 was found to be 72% effective (95% CI: 65-75%) against all serotypes. Against the 
seven serotypes included in the vaccine, VE was found to be 96% (95% CI: 93-98%) in otherwise healthy 
children and 81% (95% CI: 57-92%) in children with comorbid conditions such as cancer and sickle cell 
anemia.42 The RCT, which only enrolled healthy infants, found an efficacy against IPD of 97.4% (CI: 82.7-
99.9%).52 The full, 3+1 schedule, was found to be 100% effective (95% CI: 94-100%) compared with no 
doses.42 
Serotype replacement and the need for PCV13 
Incidence of vaccine-type IPD decreased in the US rapidly after vaccine introduction in both 
children, due to direct effects, and adults, due to indirect effects.62-65 Unfortunately, however, as rates of 
vaccine-type IPD decreased, rates of non-vaccine-type disease began to increase, a phenomenon 
termed “serotype replacement” that has also been seen to varying degrees in other countries after 
introduction of PCV7.66-68 While serotype replacement in the US did not reach high enough levels to 
cancel out the gains since PCV7, replacement was considered problematic enough to warrant the 
licensure of a 13-valent vaccine (PCV13). 
Licensure, and recommendations for use and uptake of PCV13 
PCV13, (Prevnar13™, Pfizer) includes the 7 serotypes in PCV7 and 6 additional serotypes, 1, 3, 5, 
6A, 7F, and 19A. PCV13 was licensed by FDA on the same schedule as PCV7, i.e., a three-dose primary 
series at two, four, and six months of age and a booster dose at 12-15 months of age. Additional doses 
were recommended for older children with specific underlying conditions.25 Because PCV13 is 
manufactured in exactly the same way as PCV7 it was thought to be as safe and immunogenic as PCV7, a 
hypothesis confirmed by Phase I and II trials. The extra six serotypes in PCV13 meant that the vaccine 
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would, at minimum, be no less effective than PCV7 and it was therefore not considered ethical to 
undertake a large RCT of the efficacy of PCV13. Instead, the new vaccine was licensed based on safety 
and immunogenicity data, with the requirement that post-licensure effectiveness studies would follow 
introduction.69 Safety was assessed through 13 separate clinical trials, including a total of 4,729 infants 
and toddlers.70 Immunogenicity was evaluated in a double-blind RCT of 663 infants. The study assessed 
whether or not PCV13 elicited pneumococcal IgG antibody concentrations noninferior to those elicited 
by PCV7. A cutoff of ≥0.35 μg/mL 1 month after a dose was considered noninferior. Functional 
responses via opsonophagoocytosis assay (OPA) were measured for a subset of the study population. 
The primary noninferiority criteria were met for all serotypes, except serotype 3, which failed to elicit a 
noninferior response after the fourth dose.68 
Based on these results, PCV13 was licensed by the FDA on February 24, 2010 for the prevention 
of IPD caused by one of the 13 serotypes included in the vaccine and for prevention of otitis media 
caused by one of the 7 serotypes included in PCV7.25 ACIP approved PCV13 the same day and 
recommended it replace PCV7 for routine.25  
Uptake of PCV13 in young children in the US was rapid owing to the fact that the vaccine 
replaced an existing vaccine in the routine schedule.71 By 2012, 18 months after PCV13 was introduced, 
coverage amongst 19-35-month-olds was 92.3% (+/- 0.8%) for three doses and 81.9% (+/- 1.1%) for four 
doses, only two percentage points below the corresponding coverage estimates for diphtheria, tetanus, 
and acellular pertussis (DTaP) vaccine.72 
Almost immediately after licensure, CDC began conducting a case-control study of PCV13 to 
assess vaccine effectiveness against IPD in children in the US46,69,73 CDC’s VE Study began enrolling cases 
on May 1, 2010 in 13 sites around the country and enrollment concluded on May 31, 2014. This study is 
further explained below as the parent study for the proposed research (see Chapter 3).  
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Socioeconomic disparities, pneumococcal disease and vaccination in the US 
Socioeconomic health disparities 
Healthy People 2020 defines health disparities as differences in health that are “closely linked 
with social, economic, and/or environmental disadvantage.”74 In particular, disparities “adversely affect 
groups of people who have systematically experienced greater obstacles to health” based on 
characteristics including racial/ethnic group, socioeconomic status (SES), geographic location, etc.74 
Research has shown wide disparities in health indicators ranging from cancer incidence and survival, to 
mental health, to diabetes, to infectious diseases.24,60,75,76 Theories for these disparities include in utero 
and childhood living conditions, lifetime stress, and differential access to preventive health services and 
adequate nutrition.12,16,26,76,77 
Disparities and risk of invasive pneumococcal disease 
Racial disparities in IPD incidence have been a persistent problem in the US78,79 While incidence 
rates dropped after introduction of PCV7 across all racial and ethnic groups, disparities remained. 
Indeed, while rates dropped by 89% (95% CI: 85-92%) in blacks under two years of age by 2002 
compared with only 77% (95% CI: 72-81%) in whites of the same age group, IPD rates in blacks remained 
substantially higher than rates in whites.78 Disparities remained through 2009, with the rate ratio 
comparing blacks to whites actually increasing, due primarily to rates of non-PCV7-type IPD increasing 
faster in blacks than whites.79 While PCV13-types accounted for 71% of cases in white children under 
age 5 in 2009, types included in the vaccine accounted for only 58% of cases in black children in this age 
group, meaning racial disparities are likely to persist after PCV13 introduction.79 
These racial disparities may be proxies for socioeconomic disparities, including differences in the 
prevalence of underlying conditions, higher poverty rates amongst blacks, differences in health 
insurance coverage, smoking rates, and crowding.15,79-81 Identifying and understanding these disparities 
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and their relationship with IPD is an important component of future disease control efforts, such as 
targeted immunization campaigns. 
Socioeconomic disparities, vaccination, and the vaccines for children program 
Historically, immunization rates for children of lower income households in the US for the entire 
childhood immunization schedule have lagged behind rates in children from wealthier households, 
especially amongst the youngest children.18 A major resurgence of measles in the US between 1989 and 
1991 was primarily concentrated in unvaccinated children less than five years of age, disproportionately 
from low-income, black, and Hispanic families.19-21 As a result, the Presidential Childhood Immunization 
Initiative was developed in 1993 and Congress authorized the Vaccines for Children (VFC) program the 
following year.19 Since then, the VFC program has provided free vaccines to children who are Medicaid-
eligible, uninsured, American Indian/Alaska Native, or underinsured. Implemented and managed by CDC 
since its inception, the VFC program is able to buy vaccines at a discount price and distribute them to 
Federally Qualified Health Centers (registered private physicians’ offices and public health clinics).19 In 
2011, a total of 54% of US children aged 19-35 months were VFC eligible, with the largest contingent 
qualifying due to Medicaid eligibility. Of these VFC eligible children, 52% belonged to a racial/ethnic 
group other than non-Hispanic white.19  
Remaining disparities in vaccination coverage 
A 2014 analysis of National Immunization Survey (NIS) data showed that while disparities in 
coverage of measles, mumps, and rubella vaccine (MMR), polio vaccine (IPV), and DTaP have decreased 
since the VFC program began, some disparities remained in 2011, especially when comparing non-
Hispanic whites and non-Hispanic blacks. In particular, the authors found that, “the disparities in 
estimated DTP/DTaP coverage between non-Hispanic black and non-Hispanic white children did not 
decrease significantly during 1995-2011.”19 
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These disparities were seen for pneumococcal vaccine in the early 2000s, when a number of 
temporary shortages of PCV7 resulted in amended ACIP recommendations and reduced-dose schedules. 
Children most likely to be affected by the shortages included Hispanics, non-Hispanic blacks, non-
Hispanic American Indians, children who had received prior doses from all public, hospital, military, or 
mixed-type providers (vs. private providers), children whose mother was never married or 
widowed/divorced/separated, children whose mother had not completed college, and children living in 
a household with an annual income less than 135% of the federal poverty level.82 
 In addition to truly lower vaccination coverage amongst racial and ethnic minorities, some 
research has shown that ascertainment of vaccination histories is lower amongst children reporting two 
or more vaccine providers (e.g., transient children, or those with unstable access to care), adding to 
perceived disparities.22 However, even after adjusting for these ascertainment issues, the authors 
reported that disparities in coverage persisted.22 
Individual and neighborhood level measures of socioeconomic status 
Socioeconomic status (SES) is a measure of how an individual or family’s economic position 
relates to others, usually in the same geographic area.83 While no universal definition exists, individual-
level SES is generally measured as a combination of income, education, and occupation.7,8 Race/ethnicity 
are sometimes also considered as they correlate with income level, are often associated with health 
status, and are frequently easier to obtain for research than income.13,16,84-86 Additional characteristics, 
such as health insurance status, have also been used.87 
 In addition to a mix of individual-level characteristics, SES can be measured at the neighborhood 
or area level, using factors such as unemployment rate, median area income, crime statistics, food 
scarcity, and crowding in the household, etc.7,12,13,23,24 
 In the US, the most common way to obtain neighborhood-level SES is through census areas, 
such as county, zip code, or census tract.88 Zip code has been frequently used in the past; however, zip 
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codes are defined by the US Postal Service for convenient mail delivery, are often heterogeneous with 
respect to SES, and change frequently.23 Researchers have moved toward using census tracts and blocks, 
which are defined by the US Census Bureau.88 Census tracts (CTs), the most common area-level SES 
measure in the US, generally have between 1,200 and 8,000 individuals and are maintained consistently 
over long periods of time for ease of statistical comparisons from one census to the next.88 
Past research on representativeness by socioeconomic status in VE studies in the US 
A commonly listed benefit of observational studies compared to RCTs is increased 
representativeness of the source population.89-91 RCTs generally have numerous exclusion criteria, 
whereas observational studies usually have more limited exclusion criteria.89-91 However, this benefit 
may be limited when observational studies fail to enroll a specific subset of their cases and/or controls, 
due to either an inability to locate them or to high refusal rates. If the reason a certain subset of the 
population was not enrolled is a modifier of the main exposure/disease relationship under study, then 
the results will not be generalizable to the entire target population. For example, if lower SES individuals 
are not enrolled, due to frequent moves or a lack of telephone, and the intervention under study is less 
effective in less affluent people, generalizability will be reduced.92 
Research into generalizability in VE studies is extremely limited and has focused primarily on 
adult influenza vaccine. These studies have little application to childhood vaccines as the issues arise 
from enrollment of individuals living in long-term care facilities, healthy user bias, and vaccine 
affordability issues, which are mitigated by the VFC program.93-95  
 A few studies have looked at methods, such as random digit dialing (RDD) and commercial 
databases, for identifying and recruiting individuals into observational studies in areas other than 
vaccine effectiveness. The most common methods for identifying and recruiting controls are birth 
certificates, random digit dialing (RDD), commercial databases, and neighborhood/friend controls. Each 
has potential benefits and drawbacks, with RDD likely the least useful in recent years since area codes 
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no longer indicate that an individual lives in a certain region.96-98 Commercial databases often have the 
most accurate contact information, but only include a subset of otherwise eligible individuals, making 
the source population difficult to identify.96 Birth certificate controls are likely to be the most 
representative, but the data can be difficult to acquire and contact information may be out of date, 
especially for older children, making it difficult to actually locate the individual.98 Neighborhood/friend 
controls should, in theory, allow easy matching for SES factors, but past research has found this is not 
always the case.97  
While rare for studies in most research areas to report differences between enrolled and 
unenrolled subjects, researchers of childhood leukemia and magnetic field exposure have taken an 
interest in generalizability as a way to explain significant effects found in observational studies that 
cannot be explained by a biological mechanism. A few studies have attempted to assess differences in 
participation by SES and case status and have found lower participation, particularly by controls, in 
census tracks or neighborhoods with indicators of lower SES.99-102 
All enrollment methods may be susceptible to differential enrollment by SES factors if these 
factors are associated with researchers’ ability to locate controls and/or obtain their consent.103 One 
recent study used a commercial database that classified neighborhoods into “lifestyle” clusters, using 
demographics augmented by data on consumer purchases. The “lifestyle” controls allowed the authors 
to compare SES characteristics of enrolled and unenrolled controls, finding higher enrollment rates 
amongst the wealthier clusters. In the least affluent groups, the proportion of individuals who 
consented was much higher in cases than controls.97  
 Although a lack of representativeness is likely an issue in many observation studies, most 
relegate these issues to a single sentence in the discussion of limitations. Likewise, SES both as it relates 
to selection, and as a potential modifier of the effect of vaccination, is not generally a focus of VE 
studies. 
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 PARENT STUDY: PCV13 VACCINE EFFECTIVENESS STUDY 
Active Bacterial Core surveillance system and PCV13 VE extended area surveillance  
Since 1998, CDC has conducted active, population- and laboratory-based surveillance for 
invasive bacterial infections through the Active Bacterial Core surveillance (ABCs) system.104 In addition 
to IPD, the ABCs system includes Group A Streptococcus, Group B Streptococcus, Haemophilus 
influenzae, Methicillin-resistant Staphlococcus aureaus, and Neisseria meningitides. The surveillance 
populations differ slightly for each pathogen and year, but the total population under surveillance for 
IPD in 1998 was 17.4 million persons in eight states and had expanded to 30.4 million persons in 10 
states by 2012. (Figure 1.1)105 
Cases of IPD are defined as persons with Streptococcus pneumoniae isolated from a normally 
sterile site, such as blood or cerebrospinal fluid, who are residents of the surveillance areas. ABCs 
collects standard demographic, disease course, and basic risk factor data on all cases (see Appendix 2). 
Additionally, isolates are sent to CDC for antimicrobial resistance testing and serotyping. 
The high burden of invasive disease, particularly an increase in antimicrobial resistant disease, 
identified through ABCs was one of the factors leading to the development of PCV7 in the late 1990s.2 
When PCV7 was introduced in the US in 2000, CDC conducted a matched case-control VE study within 
ABCs surveillance sites.42 This study formed the basis for the PCV13 VE Evaluation, which began in May 
2010, two months after the US release of PCV13.73 Due to relatively lower case counts in 2010 as 
compared to 2000, four additional areas were added to the catchment area for the PCV13 VE 
Evaluation: Los Angeles County (713,000 children <5 years of age), New York City (518,000 children <5 
years of age), 18 additional counties in upstate New York (66,000 children <5 years of age), and all 
members of Intermountain Health Care in Utah (213,000 children <5 years of age). 
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 Throughout ABCs and the PCV13 VE Study extended areas, site personnel routinely contact 
hospitals and laboratories that serve residents of the surveillance catchment areas. Case and isolate lists 
are requested and periodic audits ensure that hospitals and laboratories report all cases.  
IPD case definition  
Eligible cases for the PCV13 VE Study were children aged 2-59 months of age who had S. 
pneumoniae isolated from a normally sterile site, who resided in one of the surveillance areas on the 
date their culture was obtained, and had a pneumococcal serotype available.  
Case enrollment procedures 
Enrollment began on May 1, 2010 and went through May 31, 2014. Once a case was identified 
by surveillance, cases were reviewed for study eligibility. Cases meeting the study IPD definition were 
excluded if complete vaccination histories could not be obtained (Figure 3.2). Additionally, if the case 
had a previous diagnosis of IPD or the parent refused consent, the child was excluded. For eligible cases, 
site personnel conducted routine medical record reviews to complete the ABCs Case Report Form (CRF, 
Appendix 2). Site personnel then attempted to contact the parents/guardians of cases to obtain consent 
and conduct a detailed interview, which included questions about IPD risk factors such as smoking 
exposure and crowding. Parents were also asked to provide contact information for any providers who 
had administered vaccines to their child. Sites would then attempt to contact all providers and have 
them complete the Medical and Vaccine History Form (Appendix 3), which includes a detailed 
vaccination history and questions about underlying health conditions and recent antibiotic exposure.  
Control matching 
Controls were individually matched to cases on the basis of age and zip code, with a goal of 
matching four controls to each case. After enrolling a case, site personnel obtained a list of controls born 
within 14 days of the case and whose mother’s residence at the time of birth was within the same zip 
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code as the case’s residence at time of culture. Controls were then contacted, beginning with those 
controls born closest to the case and moving further out on each side of the case’s birth date. If 
insufficient numbers of controls were available within the case’s zip code, sites selected controls from 
the zip codes immediately contiguous to the case. Parents of controls were asked for consent, and then 
interviewed in the same manner as case parents. Case status could not be blinded due to logistic 
requirements at the surveillance sites.  
Exposure assessment – provider follow-up and IIS 
The main exposure for the PCV13 VE Evaluation was dichotomous – whether or not the child 
received one or more doses of PCV13. Secondary analyses considered two, three, and four doses, as 
well as mixed schedules (e.g., first two doses of PCV7, followed by two doses of PCV13). For cases (and 
matched controls) with IPD caused by one of the serotypes included in PCV7, vaccination with either 
PCV7 or PCV13 was included in the vaccine history.  
 Vaccination histories came primarily from two sources: medical records and state immunization 
information systems (IIS). Doses were considered valid if administered more than four weeks after the 
previous dose. Any doses administered before March 15, 2010 were automatically considered to be 
PCV7 as PCV13 had not yet shipped in the US. For doses administered on or after March 15, 2010, 
researchers used lot numbers provided by Pfizer to determine if a dose was PCV7 or PCV13. 
Calculation of vaccine effectiveness and primary objective 
 The primary objective for the parent study was estimation of the VE of one or more doses of 
PCV13 against IPD caused by one of the serotypes included in the vaccine.106 VE was calculated as (1-
matched odds ratio)*100.42 The matched odds ratio (mOR) was calculated from a conditional logistic 
regression model. Because IPD is a rare disease and controls were chosen using incidence density 
sampling, the odds ratio should estimate the rate ratio.107 
    
18 
 
  
 
Figure 3.1. Map of surveillance area for PCV13 VE Study, by year added to ABCs 
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Figure 3.2. Enrollment procedures for cases and controls in the PCV13 VE Study 
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 RESEARCH METHODS 
Population included in SES analysis 
Two surveillance sites, Colorado and Maryland, were not able to obtain individual-level SES 
variables and cases (and matched controls) from these two sites and were therefore excluded for 
purposes of the SES analysis (although they were included in the parent study analysis). Complete 
enrollment numbers for purposes of the SES analysis are outlined in Figure 4.1. 
Covariate assessment/definitions 
Covariates were collected from a number of sources, although not all sources were available for 
every child. A list of the variables, sources, and availability is in Table 4.1. 
ABCs case report form 
Certain SES-related characteristics are routinely collected on the ABCs CRF108 from medical 
record reviews and are available for all cases, regardless of enrollment in the PCV13 VE study. Some 
(e.g., insurance status at IPD culture, underlying condition status) are related to SES or are potentially 
useful for predicting enrollment.  
Outcome 
Outcome of the IPD episode was a binary variable, survived or died, and was collected through 
medical record review or subsequent matching with state death records. 
Severity 
Severity of IPD episode was calculated based on hospitalization and intensive care unit (ICU) 
admittance status. Cases who were admitted to the ICU were given a score of 3, the most severe. Cases 
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who were admitted to the hospital, but not the ICU, were given a score of 2. Cases who were not 
hospitalized were given a score of 1. 
Underlying condition status 
Chronic underlying chronic conditions of interest captured on the ABCs CRF are: diabetes, heart 
failure, chronic lung disease, cochlear implant, and neuromuscular disorder. Immunocompromising 
conditions captured on the ABCs CRF are: immunoglobulin deficiency, sickle cell anemia, congenital or 
acquired asplenia, leukemia, lymphoma, immunosuppressive therapy, complement deficiency, 
HIV/AIDS, cerebrospinal fluid leak, dialysis, nephrotic syndrome, solid organ malignancy, and bone 
marrow or organ transplant. Presence of either a chronic or immunocompromising condition resulted in 
the case being classified as having an underlying condition.25 
Insurance status at IPD 
The following insurance status choices are available on the ABCs CRF: private, Medicaid/state 
assistance, Medicare, military, Indian Health Service, incarcerated, uninsured, other (with a specify 
field). For the purposes of this analysis, Medicare, Medicaid, Indian Health Service, and incarcerated 
were grouped as “public/state” insurance.  
Race/ethnicity 
Races captured on the ABCs CRF are: white, black, American Indian/Alaska Native, Asian, Native 
Hawaiian/Other Pacific Islander, and unknown. Ethnicity is captured as either Hispanic or non-Hispanic. 
For purposes of this analysis, we created joint race/ethnicity categories: white, non-Hispanic, black non-
Hispanic, other (including American Indian/Alaska Native, Asian, and Native Hawaiian/Other Pacific 
Islander) non-Hispanic, and Hispanic. 
Age 
Child’s age was calculated in months as culture date – birth date. 
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Birth certificate data 
We collected demographic and prenatal care data from the birth certificates of enrolled and 
unenrolled cases and controls. Variables collected were chosen for both their reported association with 
SES and for their completeness. For example, we collected maternal race, ethnicity, and education level, 
but not paternal race ethnicity, and education. While these factors have been shown to be related to 
SES for both parents, the maternal characteristics were close to 100% complete in most study sites, 
while the paternal characteristics were frequently closer to 90% complete, if collected at all. Although 
income is not available on the birth certificate, demographic characteristics, such as race/ethnicity and 
education, correlate with income and can therefore be used to understand an individual’s SES. 
Payment status for birth 
We collected the principal source of payment/insurance status for the delivery, which is divided 
into four categories on the standard birth certificate: private insurance, Medicaid, self-pay, and other.109 
Adequacy of Prenatal Care Utilization Index 
We also collected number and timing of prenatal care visits and gestational age, which will allow 
us to estimate the Kotelchuck Index, also known as the Adequacy of Prenatal Care Utilization (APNCU) 
index.110,111 The APNCU is a four-category variable which summarizes both how early in the pregnancy a 
woman initiated prenatal care and how many total prenatal care visits the woman received. First, timing 
of initiation of prenatal care is divided into four categories (1-2 months gestation, 3-4 months gestation, 
5-6 months gestation, and 7-9 months gestation). Second, the expected number of prenatal care visits is 
calculated based on gestational age using an algorithm from the American College of Obstetrics and 
Gynecology (ACOG): one visit per month through 28 weeks’ gestation, one visit every two weeks 
through 36 weeks’ gestation, and one visit each week thereafter.111 The ratio of the actual number of 
prenatal care visits to the expected number is then calculated. For example, a woman who initiated care 
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during the first two months of gestation and had 100% of the expected prenatal care visits would fall 
into the “adequate” category. A woman who did not initiate care until the last trimester would fall into 
the inadequate category, regardless of the number of prenatal care visits she received. 
Maternal race/ethnicity 
Maternal race/ethnicity was captured on birth certificates with a minimum of the following 
categories: white, black, American Indian/Alaska Native, Asian, Native Hawaiian/Other Pacific Islander, 
and unknown. Ethnicity was captured as Hispanic or non-Hispanic. As with the CRF race/ethnicity 
variable, we created joint race/ethnicity categories: white, non-Hispanic, black non-Hispanic, other 
(including American Indian/Alaska Native, Asian, and Native Hawaiian/Other Pacific Islander) non-
Hispanic, and Hispanic. 
Maternal education 
Maternal education was divided into four categories: less than high school, high school 
equivalent, some college, or college graduate and above. 
Parent interview/provider follow-up 
For enrolled cases and controls, site surveillance personnel conducted a detailed 
parent/guardian interview, assessing demographics, IPD behavioral risk factors, and vaccine and medical 
history information. Parents/guardians were also asked to provide contact information for vaccine 
providers, who were then contacted to obtain vaccine histories. 
Income 
Parents/guardians were asked to report total household income before taxes, which was 
collected as a categorical variable with five categories in addition to “Refused” and “Don’t know.” The 
income categories were: $0-$15,000, >$15,000-$30,000, >$30,000 to $45,000, >$45,000 to $60,000, and 
>$60,000. 
    
24 
 
Caregiver education 
Parents/guardians were asked what best describes the highest level of education the primary 
caregiver completed. Categories corresponded closely with categories on the standard US Birth 
Certificate: No high school, some high school, high school graduate/GED, technical school, some college, 
college graduate, postgraduate/professional, and don’t know/refused. These categories were combined 
to match the categories for the birth certificates as follows: technical school was combined with some 
college. College graduate and postgraduate/professional were combined. 
Race/ethnicity 
Race and ethnicity were categorized in an identical way to the CRF. 
Smoking exposure 
During the interview, parents/guardians were asked a series of questions about the child’s 
exposure to secondhand smoke during the 30-day reference period (the 30 days before culture for cases 
or the corresponding month for controls). These questions included whether or not people living or 
staying in the house smoked, how many cigarettes were smoked per day, and whether the child’s 
primary or secondary caregiver smoked in a room or car with the child. Given the difficulties associated 
with accurately assessing amount of smoking and the potential for recall bias, we dichotomized smoking 
exposure (any vs. none). 
Crowding 
Parents/guardians were asked about the type of house (e.g., single family, apartment, etc.), the 
number of bedrooms, and the number of individuals living in the house during the reference period. A 
child was considered to have lived in a crowded household during the exposure period if the number of 
people per bedroom was greater than two. 
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Daycare attendance 
Parents/guardians were also asked whether or not their child attended daycare and, if so, what 
type of daycare (e.g., daycare center or home daycare), for how many hours a week, for how many 
months before the reference period, and how many children were in the same classroom or home 
daycare. As with smoking exposure, daycare attendance was dichotomized (any vs. none) to avoid 
potential recall bias issues. 
Breastfeeding 
Breastfeeding was also a dichotomous variable, counted if the parent/guardian reported any 
history of breastfeeding. 
Insurance coverage 
Parents/guardians were asked to report insurance coverage, which was categorized, as follows: 
private, Medicaid/state assistance, Medicare, uninsured, other (with a specify field).  
Influenza vaccination 
Influenza vaccination (including both seasonal and H1N1) status was collected as part of the 
provider follow-up. We counted any vaccination received in the six months before the case’s culture 
date. 
Influenza infection 
Influenza infection within the 30 days before the case’s culture date was also collected via 
provider report.  
Underlying conditions 
As part of the provider follow-up, we asked providers to report if a child had even been 
diagnosed with the same underlying conditions requested on the CRF. As with the CRF data, we 
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considered a child to have an underlying condition if they had either a chronic or immunocompromising 
condition. Both the parent interview and the provider forms included questions about these underlying 
conditions. When a discrepancy between the parent and provider existed, study staff used the 
provider’s report as this would be more likely to be complete and accurate. 
American Community Survey 
Cases and controls were geocoded, regardless of enrollment status. Geocoding was conducted 
using ArcGIS software, with a standard geocoding protocol. Census tract was merged with data from the 
American Community Survey (ACS). The ACS is an annual survey conducted by the US Census Bureau. 
Surveys are distributed to approximately 250,000 randomly selected households each month, totaling 
three million households a year. The ACS replaced the long form of the decennial census, which was last 
administered in 2000. The first full ACS was conducted in 2005 and, by 2010, the ACS was able to 
produce estimates for areas of all population sizes, using information collected from January 2005-
December 2009.106 We used the five year estimates from 2009-2013. 
 The ACS includes demographic information, such as the distribution of racial and ethnic groups 
with a census tract, the number and percent of individuals indicating multiple races, age and gender 
distributions, distribution of educational level and primary and secondary languages, and percent of 
households with a female head of household. It also includes number and percent of poor, as well as 
distribution of income brackets and median household income, percent with private, public, and no 
insurance, distribution of different job classes (e.g., sales, professional, executive-level, etc.), 
employment rates and number of households on public assistance, number of renter vs. owner-
occupied housing units, percent who own a car, rental or mortgage price, and distribution of crowding. 
Detailed information on variables used in each aim will be provided below, as appropriate. 
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Ethics approval 
 Both the parent study and the SES analyses were approved as non-research by the Institutional 
Review Board at CDC as they was part of an assessment of the implementation of a public health 
intervention. The SES analyses were also approved by the Institutional Review Board of the University of 
North Carolina, Chapel Hill, USA.   
  
    
28 
 
 
 
  
 
* Includes controls up to and including the last enrolled controls. Children that were not needed because 4 controls 
had already been enrolled for the case, are excluded. 
Figure 4.1. Enrollment numbers for SES analysis 
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Table 4.1. Variables, sources of information, and availability by case and enrollment status 
  
Variables Source Cases Controls 
Enrolled Unenrolled Enrolled Unenrolled 
IPD severity, outcome, 
underlying condition status, 
insurance status at IPD, 
race/ethnicity, gender, age 
ABCs CRF     
Income, caregiver education, 
race/ethnicity, smoking 
exposure, crowding, daycare 
attendance, breastfeeding, 
insurance status at IPD, 
influenza vaccination, 
influenza infection, underlying 
conditions 
Parent 
interview & 
provider 
follow-up 
    
Payment status for birth, 
number and timing of prenatal 
care visits, gestational age, 
maternal education, maternal 
race/ethnicity 
Birth certificate     
Numerous ACS 
(geocoding) 
    
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Table 4.2. American Community Survey variables included in prediction models for enrollment. 
Category Variable name ACS Table 
D
em
o
gr
ap
h
ic
s 
White, non-Hispanic 0005 
Hispanic, any race 0005 
Citizen, born in US 0009 
Immigrant, entered US in 2010 or later 0010 
Born in North America 0010 
Born in Europe 0010 
Born in Asia 0010 
Born in Africa 0010 
Born in Latin America 0010 
Child living in 2-parent household 0012 
Child is native-born 0012 
Citizen, naturalized in 2010 or later 0012 
Born in same state as current residence 0013 
Speaks English well 0014 
Never married 0014 
Lacks high school diploma (of those ≥25 years) 0043 
Veteran (of those ≥25 years) 0073 
Private insurance 0116 
W
e
al
th
 
Median income 0015 
Living below 100% of poverty line 0015 
Lived in same house 1 year ago 0016 
Lived abroad 1 year ago 0016 
Received public assistance in past 12 months 0034 
Lived in poverty in past 12 months 0048 
Earns < $30,000 per year 0059 
Earns ≥$60,000 per year 0059 
Gini Index 0063 
Per capita income in past 12 months 0065 
W
o
rk
 
Drives alone to work, workers ≥16 years of age 0023 
Workplace in same county as residence 0023 
Night shift 0023 
Commute time ≥ 60 minutes 0023 
No vehicle available for commute 0023 
Disabled 0058 
Mean hours worked 0078 
Unemployed 0079 
Working class (includes workers in sales/office, service, production, 
transportation, moving, construction, and maintenance) 
0080 
H
o
u
se
h
o
ld
 
Owner occupied housing units 0019 
Size of household 0028 
Number of workers in household 0028 
Female head of household in household with children <18 years, no 
husband 
0034 
2-parent household, children <18 years 0034 
Unmarried partner living in household 0034 
Child lives with biological parent 0034 
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Household with no children < 18 years of age 0060 
Householder < 25 years of age 0060 
Householder ≥ 65 years of age 0060 
Occupied housing units 0103 
Housing units for rent 0103 
Housing units for migrant workers 0103 
House with > 1.0 occupant per room 0103 
Median rooms in housing units 0104 
Median year structure built 0105 
Median year householder moved into unit 0105 
Housing unit with complete plumbing facilities 0105 
Housing unit with complete kitchen facilities 0105 
Median rent 0106 
Median rent as percent of income 0106 
Median monthly housing costs 0108 
Owner-occupied homes worth < $300,000 0107 
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 ANALYTIC METHODS 
Aim 1 
Evaluate whether zip code matching results in a similar distribution of SES in cases and controls; estimate 
the amount of residual confounding and appropriately adjust the main VE estimate. 
Identification of confounders 
 Confounders for adjustment were identified using a directed acyclic graph (DAG). DAGitty.net 
(version 2.2) software was used to identify minimally sufficient confounding subsets (Figure 5.1).112-115 
Zip code matching ensured enrolled cases and eligible controls had similar aggregate SES at the zip code 
level, but not at the census tract or at the individual level. Our DAG, however, included these census 
tract and individual SES measures to determine if zip code was an adequate proxy. Multiple minimally 
sufficient confounding subsets were identified, with substantial overlap between them. We selected one 
minimally sufficient subset for our primary analysis based on the completeness of the variables included 
(i.e., least number of matched pairs dropped due to missing data). 
Comparison groups 
We explored the potential for residual confounding in two ways, both of which explored 
differences between enrolled cases and a group of controls. First, using available data on all enrolled 
cases and all eligible controls (regardless of enrollment) we assessed whether differences existed 
between the groups. If no differences exist between enrolled cases and eligible controls, this would 
indicate zip code matching theoretically controlled for measured confounders. In other words, if the two 
groups are similar, this indicates that, in the absence of selection issues, matching on zip code resulted 
in controls that were exchangeable with cases, with respect to measured SES characteristics. If however, 
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differences between enrolled cases and eligible controls exist, this would indicate zip code matching had 
failed to control for individual SES.  
Second, we restricted our analysis only to enrolled cases and enrolled controls. This allowed us 
to assess how selection issues, such as failure to locate or enroll controls in the study, affected our final 
study population. The meaning of the results of this step is dependent on the results of the first step. If 
enrolled cases were similar to eligible controls and enrolled controls, this would indicate that zip code 
matching was successful (i.e., enrolled cases were similar to eligible controls) and there was no selection 
bias. Our study population would therefore be exchangeable with respect to measured SES. If, however, 
enrolled cases were similar to eligible controls, but not to enrolled controls, this would indicate selection 
bias. If zip code matching failed (enrolled cases were not similar to eligible controls), any similarity 
between enrolled cases and enrolled controls would likely be due to chance. 
Control for residual confounding 
 We used the same primary outcome, VE of one or more doses of PCV13 against one of the 
serotypes included in the vaccine, as the parent study. VE against serotypes not included in PCV13 was 
also calculated as a negative control. Assuming no cross-reactivity with vaccine serotypes, VE against 
non-vaccine types should by zero, so an estimate significantly different from zero would indicate a 
problem with the analysis. 
 Unadjusted VE was calculated via conditional logistic regression with only vaccination status 
included in the model. Adjusted (full) models were run, which included vaccination status and each of 
the minimally sufficient confounding subsets identified from our DAG. Since each of the full models 
included numerous variables, any one of which could be missing for a particular child, a reduction in 
sample size was expected compared to the unadjusted model. We therefore chose as our primary 
minimally sufficient subset the model with the most discordant pairs.  
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We considered an absolute change in the VE of 5% between the full and unadjusted models 
(e.g., a change from 95% to 90% effectiveness) to be an indication of meaningful change (i.e., 
meaningful residual confounding). Experience with tracking individual PCV7 serotypes after PCV7 was 
introduced indicated that a difference of 7% in the VE could result in large differences in post-vaccine 
cases. For example, serotypes 14 and 19F, both of which were included in PCV7, had pre-vaccine rates of 
63.3 and 21.8 cases per 100,000, respectively, in the US. VE for serotype 14 was estimated as 94% (95% 
CI: 81-98%) and VE for serotype 19F was estimated as 87% (95% CI: 65-95%). By 2004, only 14 
breakthrough cases of serotype 14 were identified in ABCs, compared with 45 cases of serotype 
19F.34,42,66 This difference, especially given the much higher rates of serotype 14 in the pre-vaccine era, 
indicated a difference of 7% would be important, so to be conservative for purposes of the current 
analysis, we considered a slightly lower difference to be meaningful.  
Aim 2 
Assess generalizability in a population-based case-control study by: 
(a) assessing whether enrollment rates differ with respect to SES, and 
(b) determining whether SES is an effect measure modifier of the estimated vaccine effectiveness. 
External validity, or generalizability, is the measure of how well results from a study pertain to 
individuals in the target population.116-118 Study results may fail to generalize to a target population 
under several circumstances.6,116  A key reason that studies fail to be generalizable is when both of the 
following criteria are met: (a) selection/enrollment into the study is differential with respect to variable 
X (i.e., the study population is not representative of the source population with respect to variable X, 
which is usually a potential confounder), and (b) variable X modifies the exposure/outcome relationship 
under study.6,116 
It is important to note that in matched case-control studies, controls need not be representative 
of the source population with respect to the matching factor(s). In fact, if matching is done correctly, 
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controls should resemble enrolled cases on the matching factor. This analysis, therefore, focuses on 
representativeness of enrolled cases with respect to eligible cases and leaves questions concerning 
controls for other analyses.  
Socioeconomic Position Index 
 In addition to the ACS variables used in Aim 1, we calculated a composite index for SES based on 
work done by the Public Health Disparities Geocoding Project.24 The Socioeconomic Position (SEP) Index 
includes ACS variables measuring working class, unemployment, poverty, education, home prices, and 
median family income. Together these are meant to capture the major SES constructs of wealth, 
education, and occupation. The SEP Index is created by first calculating the percent of each of the ACS 
variables included. Then, a standardized z-score is calculated for each variable: 
𝑍𝑖𝑗 = (𝑋𝑖𝑗 −𝑚𝑗)/𝑠𝑗 
Where Xij is the value of variable j for area i, mj is the mean of variable j across all areas, and sj is the 
standard deviation of variable j over all areas.24 The sum of the Z scores for each variable is then the 
value of the composite index. 
Choosing variables for modification assessment 
Because we had access to many SES-related variables through the case report form, birth 
certificates, and ACS, it was not practical to assess every variable for effect measure modification 
(EMM). Instead, we chose variables to assess for EMM in two ways. First, we decided a priori to assess 
as modifiers the SEP Index and the any individual-level variables which had p-values <0.2 in the 
exploratory analyses for differences between enrolled and unenrolled. P-values were calculated for 
continuous and categorical predictors via two-sided Wilcoxon rank sum test and Fisher’s exact test, 
respectively. 
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Second, to ensure we did not miss any variables for the EMM assessment that may be strong 
modifiers and related to representativeness, we used predictive modeling to select additional ACS 
variables to assess for EMM.  
Predictive model 
Many of the available ACS variables measured similar metrics (both to other ACS variables and 
to the individual variables); therefore, we fit a series of models to narrow the selection. All models fit 
were logistic regression, using backward selection and retaining variables with a p-value of <0.2. 
Individual model 
We first fit a single predictive model including all individual-level variables: severity, outcome, 
underlying condition status, child’s race/ethnicity, insurance status at IPD, mother’s education, mother’s 
race/ethnicity, APNCU Index, source of payment for birth, and interaction terms between child’s race 
ethnicity and maternal education and between child’s race/ethnicity and APNCU Index. The model was 
required to retain severity, outcome, underlying condition status, child’s race/ethnicity, and insurance 
status at IPD.  
ACS models 
We divided the ACS variables into four categories – demographics, wealth, work, and household 
characteristics – for inclusion in separate models to reduce the number of ACS variables used. Four 
models were run, including all individual-level variables retained from the first model and each category 
of the ACS variables. Lastly, we fit the final predictive model, which included all the individual-level 
variables and interaction terms (regardless of whether they were retained in the first model) and any 
variables retained in the ACS models. As with the first model, we required the model to retain the case 
report form variables. 
    
37 
 
Assessment of effect measure modification 
Any variables included in the final model predicting enrollment were assessed as potential 
modifiers, in addition to the SEP Index and individual-level variables chosen a priori. All the individual-
level variables were already categorical. We did not include variables (i.e., severity of IPD, outcome 
status) that are not applicable to controls. Additionally, variables obtained from the case report form for 
cases (child’s race/ethnicity, underlying condition status, and insurance status at IPD) were not available 
for controls (since no case report form is completed for controls); however, these variables were 
collected as part of the parent interview/provider follow-up for enrolled children and could therefore be 
assessed for EMM. The ACS variables were continuous, so we dichotomized them at the median for the 
EMM analysis (Table 5.1). To assess variables as modifiers, we fit conditional logistic regression models 
for each variable with IPD caused by one of the 13 serotypes included in the vaccine as the outcome, 
receipt of one or more doses of PCV13 as the exposure, and an interaction term between each variable 
of interested and PCV13 receipt.119 Because power to assess interaction terms is reduced, we used a p-
value <0.2 as our cutoff for the likelihood ratio chi-square value for the interaction term and then did a 
Bonferroni adjustment by the total number of variables assessed for EMM to account for multiple 
comparisons. Therefore, α<0.015 for the likelihood ratio test was considered an indication of 
modification and cause for concern about generalizability. 
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Figure 5.1. Causal diagram showing the relationship between vaccination status, IPD, and confounders. 
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Table 5.1. Operational definitions of ACS variables included in final prediction model. 
Category Variable name Variable description Cut point (median) 
for EMM analysis 
Demographic White race Percent of individuals identifying as 
white, non-Hispanic 
48.3% 
Wealth Household 
income <$30,000 
Household income in the past 12 
months (in 2013 inflation-adjusted 
dollars) 
28.0% 
 Household 
income ≥$60,000 
Household income in the past 12 
months (in 2013 inflation-adjusted 
dollars) 
40.4% 
Work Working class Percent of individuals reporting jobs 
in sales, service (except protective), 
production, transportation, and 
material moving, natural resources, 
construction and maintenance 
61.4% 
 Disabled Percent of individuals with a 
disability 
10.3% 
 Mean usual hours 
worked 
Mean number of hours worked 
annually 
37.9 hours 
Household Units occupied Percent of occupied housing units 92.3% 
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 BIAS WITH RESPECT TO SOCIOECONOMIC STATUS: A CLOSER LOOK AT ZIP CODE 
MATCHING IN A PNEUMOCOCCAL VACCINE EFFECTIVENESS STUDY 
Overview 
In 2010, 13-valent pneumococcal conjugate vaccine (PCV13) was introduced in the US for 
prevention of invasive pneumococcal disease in children. Individual-level socioeconomic status (SES) is a 
potential confounder of the estimated effectiveness of PCV13 and is often controlled for in 
observational studies using zip code as a proxy. We assessed the utility of zip code matching for control 
of SES in a post-licensure evaluation of the effectiveness of PCV13 (calculated as [1-matched odds 
ratio]*100). We used a directed acyclic graph to identify subsets of confounders and collected SES 
variables from birth certificates, geocoding, a parent interview, and follow-up with medical providers. 
Cases tended to be more affluent than eligible controls (for example, 48.3% of cases had private 
insurance vs. 44.6% of eligible controls), but less affluent than enrolled controls (52.9% of whom had 
private insurance). Control of confounding subsets, however, did not result in a meaningful change in 
estimated vaccine effectiveness (original estimate: 85.1%, 95% CI 74.8-91.9%; adjusted estimate: 82.5%, 
95% CI 65.6-91.1%). In the context of a post-licensure vaccine effectiveness study, zip code appears to 
be an adequate, though not perfect, proxy for individual SES. 
Introduction 
Socioeconomic status (SES) is increasingly understood to be a fundamental cause of disease due 
to the persistent association between low SES and poor health outcomes, despite substantial advances 
in prevention and treatment of disease.7,86,120 This association is concerning, especially in the US, where 
substantial differences in access to healthcare, nutritious foods, and physical activity exist between 
more and less affluent individuals and neighborhoods.7,15-17,26,75,86,120 While no single definition of SES is 
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universally accepted, individual-level SES is generally measured as a combination of income, education, 
and occupation, which in turn provide surrogate measures of resources, prestige, knowledge, and 
power.7,8,12,115,120-122 Race, ethnicity, and health insurance status may also be considered markers of SES, 
because these factors provide insights into access to resources, knowledge and power, and are 
frequently easier to obtain for research than income or education levels.13,16,84-87  
When SES is not the exposure of interest and instead measured to control for potential 
confounding of an exposure-disease relationship, most researchers will simply match on SES or control 
for SES during analysis, depending on the study design.  Whether SES is examined as an exposure or 
confounder, it is paramount that the variable serve as an accurate surrogate of the construct that one 
intends to measure.  For example, if neighborhood-level income is being used as a surrogate for 
individual level income level, one must be confident that this cross-level inference is valid.123,124 
Because SES is often clustered geographically and individual-level data can be difficult to obtain, 
researchers often assess SES ecologically, for example by using neighborhood-level measures, such as 
prevalence of poverty by zip code.125-127 For example, research conducted using cases identified through 
disease surveillance systems frequently uses zip code as a proxy for individual SES. Surveillance systems 
generally incorporate addresses, but rarely include characteristics such as personal or household 
income, educational attainment, or occupation, which require follow-up with individual cases.12,126 Using 
zip code is a relatively easy way to measure SES, but requires the assumption that zip code is an 
adequate proxy for individual or household level SES.124,128  
One type of study in which potential confounding by SES is of concern is post-licensure vaccine 
effectiveness studies, frequently conducted after a vaccine is introduced and typically using a case-
control study design. Because both the exposure (vaccination) and outcome (infectious disease) may be 
associated with SES, the potential for confounding may exist and researchers therefore frequently 
match on zip code.17-22,42,44,75,129,130 Zip code matching, however, only ensures that eligible controls are 
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similar to enrolled cases at the zip code level. Differences may remain between the groups at smaller 
area levels (i.e., census tract) or at the individual level. Thus, even after matching on zip code, 
confounding by individual SES may remain.  To date, little research has explored whether matching on 
zip code provides adequate control for individual SES in vaccine effectiveness studies in the US.23,42,44,129 
We were concerned about confounding by individual SES in a zip code-matched case-control 
study of 13-valent pneumococcal conjugate vaccine (PCV13) effectiveness.119 PCV13 was licensed for use 
in children in the US in February 2010 and replaced the effective, but more limited, 7-valent vaccine 
(PCV7).68,73 SES, including income, educational attainment, and related factors (e.g., asthma, smoking 
exposure), has been frequently shown to be associated with both vaccination status and risk of IPD and 
is therefore of concern as a potential confounder.18,19,21,22,78,79,82 Zip code matching was used to control 
for SES. The purpose of the present study was to determine whether this approach provided adequate 
control for confounding at the census tract and individual levels or if additional control of confounding 
was necessary. 
Methods 
Enrollment methods 
Details of the vaccine effectiveness study and results of the primary analysis have been 
previously published.119 Briefly, cases of IPD were identified through the Centers for Disease and Control 
and Prevention’s (CDC) Active Bacterial Core surveillance, an active population- and laboratory-based 
surveillance system for invasive bacterial diseases in ten sites around the US.105 Three other sites with 
similar case identification methods were added to increase numbers of cases: New York City, Los 
Angeles County, and the State of Utah. Eligible case-children were identified through routine 
surveillance between May 1, 2010 and May 31, 2014 who were 2-59 months of age with a 
pneumococcal serotype available.73 Informed consent was obtained for all enrolled cases and controls. 
Both the parent study and the current analysis were approved by institutional review boards (IRB) at 
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CDC and the surveillance sites. The current analysis was also approved by the University of North 
Carolina, Chapel Hill IRB.   
Enrollment procedures for case and controls have been described previously.119 Briefly, study 
staff contacted parents/guardians of case and control children via telephone to obtain consent, 
ascertain information on factors potentially related to disease, and gather contact information for 
vaccine providers; providers were then asked for detailed medical and vaccine history information.14,42 
Once a case-child was enrolled, staff obtained from local birth registries a list of 20-40 children born in 
the case-child’s zip code within 14 days of the case-child’s birth. If four controls could not be enrolled 
from with a case-child’s zip code, additional controls were obtained from adjacent zip codes. Controls 
were then enrolled in order, starting with the control-child whose birth date was closest to the case and 
then ranked alphabetically. At least 10 attempts to enroll a control were made at different times of the 
day and on different days of the week before moving on to the next potential control.  
The main analysis excluded children who could not be located, whose parents refused, whose 
vaccination history could not be verified, who had a recurrent IPD episode (cases only), were in foster 
care (controls only), had died for any reason (controls only), or were the sibling of a previously enrolled 
child (controls only), and residents of long-term care facilities. Finally, for the purposes of this analysis, 
cases and controls from two surveillance sites, Colorado and Maryland, were excluded because 
individual-level birth certificate data were not available to investigators. 
Identification of confounders 
To identify confounders for adjustment in analytic model of vaccine effectiveness, we constructed a 
directed acyclic graph (DAG).112,113,115 Potential confounders were identified from past research, and 
DAGitty.net (version 2.2) software114 was used to identify minimally sufficient confounding subsets for 
adjustment. Zip code matching ensured that enrolled cases and eligible controls had similar aggregate 
SES at the zip code level, but not at the census tract or at the individual level. Our DAG, however, 
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included these census tract and individual SES measures to determine if zip code was an adequate 
proxy. Multiple minimally sufficient confounding subsets were identified, with substantial overlap 
between them. We selected one minimally sufficient subset for our primary analysis based on the 
completeness of the variables included (i.e., fewest matched pairs dropped due to missing data). In 
addition to confounders identified by our DAG, we also assessed distributions of other SES-related 
characteristics available from birth certificates and the US Census Bureau’s American Community Survey 
(ACS) by case-control status.  
Values of confounders were identified from three sources. First, we used the parent interview 
and provider follow-up to obtain information on smoking exposure and daycare attendance (any vs. 
none in the 30 days before the case’s culture date), influenza vaccination or infection within the 
previous six months, household income, primary caregiver education, insurance status at time of IPD 
culture, underlying condition status (asthma, chronic lung or heart disease, diabetes, cerebrospinal fluid 
leak, cochlear implant, sickle cell disease, congenital or acquired asplenia, HIV/AIDS, chronic renal 
failure, nephrotic syndrome, malignant neoplasm, leukemia, lymphoma, solid organ transplant, 
congenital immunodeficiency25), breastfeeding (ever vs. never), presence of other children in the 
household, and household crowding (>2 people per room).14,17,22,79,131 Because only enrolled children 
were interviewed, these variables were not available for unenrolled controls. 
The second source of confounder information was data from birth certificates of enrolled and 
unenrolled children. These variables included timing of initiation of prenatal care and gestational age 
(which were used to calculate the Adequacy of Prenatal Care Utilization Index110,111), maternal 
race/ethnicity, maternal education, and insurance status at birth.109 Prenatal care, while not a typical 
SES measure, is likely to be related to access to and utilization of health services. Finally, eligible cases 
and controls were geocoded, allowing linkage with census tract information obtained via the ACS, which 
includes such neighborhood measures as income, racial/ethnic distribution, and proportion living below 
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the poverty line, among many others.106 Of these, residence in a neighborhood with >25% foreign born 
individuals was included on our DAG. 
Comparison groups 
We explored the potential for residual confounding in two ways, both of which compared 
differences between enrolled cases and a group of controls. First, using available data on all enrolled 
cases and all eligible controls (regardless of enrollment) we assessed whether differences existed 
between the groups. If no differences existed between enrolled cases and eligible controls, this would 
indicate zip code matching theoretically controlled for measured confounders. In other words, if the two 
groups were similar, this indicates that, in the absence of selection issues, matching on zip code resulted 
in controls who were exchangeable with cases with respect to measured SES characteristics. If, however, 
differences between enrolled cases and eligible controls existed, this would indicate zip code matching 
had failed to control for individual-level SES.  
Second, we restricted our analysis to enrolled cases and enrolled controls, allowing us to assess 
how selection issues such as failure to locate or enroll controls in the study affected our final study 
population. The meaning of the results of this step is dependent on the results of the first step. If 
enrolled cases were similar to eligible controls and enrolled controls, this would indicate that zip code 
matching was successful (i.e., enrolled cases were similar to eligible controls) and there was no selection 
bias. Our study population would therefore be exchangeable with respect to measured SES. If, however, 
enrolled cases were similar to eligible controls, but not to enrolled controls, this would indicate selection 
bias. If zip code matching failed (enrolled cases were not similar to eligible controls), any similarity 
between enrolled cases and enrolled controls would likely be due to chance. 
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Statistical methods 
Descriptive analyses of univariate distributions in cases and controls were assessed for 
confounders identified in the minimally sufficient confounding subset, as well as related characteristics 
available from birth certificates and geocoding. Most variables collected from the parent interview, 
provider follow-up, and birth certificates were categorical in nature and left in this form in the initial 
analysis. Categories were combined for modeling purposes when sample sizes in individual strata were 
too low. The results of conditional logistic regression models with enrolled children only, including all 
confounders identified in the minimally sufficient confounding subsets, were compared to the original 
model, which included only the matching factors of age and zip code. The exposure was receipt of one 
or more doses of PCV13 at least 14 days before pneumococcal culture (or the matched case’s culture 
date for controls).  
The primary outcome for the parent study was PCV13-type IPD, which was also the focus of the 
current analysis. We used cases caused by serotypes not included in PCV13 as negative controls. That is, 
assuming no cross-reactivity with vaccine-types, vaccine effectiveness against non-vaccine types should 
be zero, so a high (or low) significant estimate would indicate a problem with the methods or analysis.  
Vaccine effectiveness is calculated as (1 – matched odds ratio)*100% for a rare disease, such as IPD.42 An 
absolute difference in the vaccine effectiveness of 5% between the full and original models was 
considered an indication of meaningful confounding (e.g., a change from 95% to 90% effectiveness).  
Results 
Enrollment 
Of 1,040 eligible cases, we enrolled 661 (63.6%) children. We identified 12,305 potential 
controls, of whom, 255 were excluded because they had moved out of the surveillance area by the time 
of the corresponding case’s IPD diagnosis and were therefore ineligible for enrollment. Of the 12,050 
eligible controls, 2,774 (23.0%) were enrolled. The primary reasons for non-enrollment were an inability 
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to locate/contact the parent/guardian (7,516, 81.0%) and refusal (1,600, 17.2%). In addition, 160 (1.7%) 
were not enrolled for other reasons, including the lack of a vaccine history, a language barrier, or being 
in foster care.  
The 661 enrolled cases came from 557 zip codes and 632 census tracts (Table 4.1). Of the 12,050 
eligible controls, the majority, 8,690 (72.1%), came from the same zip code as their matched case. 
However, only 1,250 (10.4%) came from the same census tract as their matched case. A similar pattern 
was seen among enrolled controls, with, 1,921 (69.3%) coming from the same zip code as their matched 
case and 271 (9.8%) coming from the same census tract as their matched case. 
Differences between enrolled cases and eligible controls 
Based on birth certificate data, enrolled cases tended to have slightly more affluent mothers 
than eligible controls. For cases, 44.1% of mothers had no college education, compared with 49.3% of 
mothers of mothers of eligible controls (Table 4.2). Additionally, 48.2% of cases had private insurance at 
birth, compared with 44.9% of controls. Mothers of cases and eligible controls were similarly likely to 
have had at least adequate prenatal care utilization (70.4% of cases vs. 69.8% of controls). 
A similar, though less pronounced, pattern was seen for neighborhood level characteristics. In 
census tracts of enrolled cases, a median of 15.4% of individuals lived below the poverty level, 
compared with a median of 16.5% in census tracts of eligible controls. In addition, 31.3% of cases came 
from census tracts with more than a quarter of the population being foreign born, compared to 34.8% of 
eligible controls. We did not find substantial differences in median income, crowding, or income 
inequality (as measured by Gini Index) between cases and eligible controls (Table 4.2). 
Differences between enrolled cases and controls  
Unlike eligible controls, enrolled controls had a higher SES than enrolled cases. Based on 
information collected during the parent interview, 53.8% of cases came from households with incomes 
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above $30,000/year, compared to 62.1% of controls. Less than half (44.4%) of cases had private 
insurance at the time of IPD diagnosis, vs. 52.7% for controls. Primary caregivers of cases were slightly 
less likely to have at least some college education (67.3% of cases vs. 70.6% of controls). Enrolled 
controls were also more likely to have breastfed and less likely to have an underlying condition, have 
attended daycare, be passively exposed to smoking (Table 4.2). The birth certificate variables showed 
fewer differences between enrolled cases and controls. The two groups had a similar distribution of 
prenatal care utilization (70.4% of cases vs. 72.5% of controls with adequate or adequate plus prenatal 
care utilization), while cases were slightly less likely to have had private health insurance at the time of 
birth (48.2% of cases vs. 52.9% of controls). 
DAG analysis and adjusted models 
In the main analysis, the unadjusted vaccine effectiveness against PCV13-type disease was 
86.0% (95% CI: 75.5 to 92.3%).119 Once we excluded the children from Maryland and Colorado, the 
original estimate (controlling for only the matching variables) was 85.1% (95% CI: 73.8 to 91.9%), similar 
to that from the main analysis. We identified four minimally sufficient confounding subsets. The subset 
including age, asthma, breastfeeding, presence of children in the household, underlying condition 
status, influenza vaccination status, household income, insurance type at IPD diagnosis, race, smoking 
exposure and zip code had the fewest missing values and was chosen for the primary analysis (Table 3). 
The adjusted vaccine effectiveness estimate was 83.5% (95% CI: 67.3 to 91.6%). The remaining three 
subsets yielded estimates of vaccine effectiveness between 81.2 and 83.1%, with 95% CIs ranging from 
55.1 to 93.6% (Table 3). None of the vaccine effectiveness point estimates from the adjusted models 
differed by an absolute value of 5% or more from the original model, so we used the original model as 
our “final” model. As expected, our negative control (vaccine effectiveness against non-vaccine types) 
yielded low point estimates, with wide confidence limits, all of which crossed the null value (vaccine 
effectiveness=0).  
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Discussion 
We assessed the use of zip code matching to control for individual-level SES in a matched case-
control study of the vaccine effectiveness of PCV13 in children less than five years of age in the US. We 
found enrolled cases to be slightly more affluent than eligible controls, but slightly less affluent than 
enrolled controls, as measured by census tract and individual SES variables from parent interviews, 
provider follow-up, and birth certificates. Adjustment for these variables, however, did not substantially 
change our estimate of vaccine effectiveness, indicating that zip code matching was an adequate proxy 
for individual SES in our study and that our previously-published unadjusted estimates should be valid 
with respect to individual SES. 
We assessed a number of SES-related variables beyond those identified as confounders in our 
DAG. SES is a general term encompassing numerous aspects of an individual or neighborhood and 
cannot be perfectly measured by any one or any series of characteristics. The exact mechanism(s) by 
which SES is related to IPD risk is unknown, but clearly multifaceted (i.e., related to conventional SES 
measures such as household income and crowding, but also to less conventional measures, such as 
smoking exposure and asthma). Therefore, the potential for unmeasured confounding could be 
substantial, so exploring a broader subset of SES characteristics is ideal.  
Our finding that enrolled cases were slightly more affluent than eligible controls was expected, 
given that enrolled cases are the subset of the population of eligible cases we were able to locate and 
enroll, whereas eligible controls represent the entire area. More affluent individuals may be more likely 
to have landlines or retain a single telephone number over time (making them easier to reach) and may 
have increased use of and trust in the medical system (making them more likely to agree to 
enrollment).5,9,132 The differences indicate that (as expected) zip code may not be a perfect proxy for 
individual SES in our population. However, the differences did not have a substantial effect on our 
estimate of vaccine effectiveness. Thus, zip code may suffice for matching purposes for SES, especially if, 
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as in this study, data are available to assess differences and adjust for or interpret results appropriately. 
Our second comparison explored the differences between enrolled cases and enrolled controls, which 
takes into account both zip code matching and our ability to locate and enroll controls. In this analysis, 
we found that enrolled cases were slightly less affluent than enrolled controls. This may be because 
parents of cases were easier to locate (medical records from the IPD episode provide more current 
contact information) and had an incentive to participate (their child recently had a major illness), and 
therefore enrolled cases may have been more representative of all eligible cases whereas enrolled 
controls may have represented only the most affluent of eligible controls who were successfully located 
and contacted and gave consent for participation. 
Differences in both comparisons were smaller when census tracts were compared as opposed to 
individual-level data (either from the parent interview or birth certificates). This likely reflects the fact 
that census tract is an ecologic measure and thus represents the average for a geographic area, rather 
than individual differences. Additionally, there was overlap in census tracts, blunting the differences 
between groups. 
Adjustment for the primary minimally sufficient confounder subset resulted in little change in 
the vaccine effectiveness point estimate (1.6% absolute change). Similarly, none of the vaccine 
effectiveness point estimates from the additional confounder subsets identified reached the 5% 
absolute change we decided a priori to be meaningful. This suggests that our original (unadjusted except 
for the matching factors) estimate of vaccine effectiveness was not substantially biased – and therefore 
that traditional zip code matching was adequate for control of individual-level SES. Less than expected 
confounding by SES may also be due to the success of the Vaccines for Children program, which has 
operated since 1994 and has reduced immunization coverage disparities in many routine childhood 
vaccines.133  
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Our study had limitations. We were not able to conduct interviews with unenrolled controls and 
therefore had to rely on data from geocoding and birth certificates to assess SES. Census tracts, while 
more granular than zip codes, still provide only a group-level estimate of SES. Census tract income, for 
example, may not be an adequate proxy for individual income and may be simultaneously measuring 
the effect of low individual income and living in a poorer neighborhood. Birth certificates, meanwhile, 
provide individual-level information, but their accuracy can vary by state.134-136 Additionally, birth 
certificate variables were not available for cases born outside the state where they lived at the time of 
their IPD episode. While more information was available for enrolled children, data from parent 
interviews (i.e., behavioral risk factors) could be subject to recall bias. We attempted to mitigate this by 
using measurements less prone to poor recall (e.g., any smoking exposure instead of number of 
cigarettes per day), but this could potentially result in other forms of misclassification. 
 Our study had a number of strengths, including multiple measures of SES at both the 
neighborhood- and individual-level from the parent/guardian, birth certificate, and census tract. 
Because we had access to SES information on unenrolled controls, we were able to assess both the 
theoretical use of zip code as a proxy for individual SES, as well as effects of selection methods on the 
real world study population. And while birth certificates and geocoding may not be the ideal way to 
estimate individual SES, they provide more information on eligible children than is usually available to 
researchers, especially in such a large surveillance system. Such data can provide insight into the study 
population and how selection may affect internal validity, as well as potentially helping identify SES-
related risk factors for disease.  
 In summary, we found that, despite some differences between cases and controls, zip code 
matching achieved its intended purpose and our estimated vaccine effectiveness is internally valid with 
respect to individual-SES. Our results should be broadly generalizable to other vaccine effectiveness 
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studies in the US, as well as studies of other health outcomes utilizing similar control identification and 
participant enrollment methods.  
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Table 6.1. Number of unique zip codes and census tracts for eligible and enrolled children, by case 
status and serotype of disease 
 Enrolled cases Eligible controls Enrolled controls 
Total N 
Unique zip codes 
Unique Census Tracts 
661 
557 
632 
12,050 
1,209 
4,835 
2,774 
577 
2,126 
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(a) Parent interview/medical provider  
Characteristic Enrolled cases 
(n=661) 
Eligible controls 
(n=12,050) 
Enrolled controls 
(n=2,774) 
Median age, months (range) 21 (2-59)  21 (2-60) 
Asthma, n (%) 128 (19.4)  321 (11.6) 
Chronic condition, n (%) 51 (7.7)  32 (1.2) 
Immunocompromising condition, n (%) 111 (16.8)  82 (3.0) 
Breastfeeding, n (%)    
Ever breastfed 480 (73.2)  2224 (80.4) 
Currently breastfed 52 (7.9)  303 (11.0) 
Crowding (>2 people per bedroom) 111 (16.8)  414 (15) 
Day care attendance, n (%) 313 (47.5)  957 (34.6) 
Smoking exposure, n (%) 134 (20.5)  443 (16.1) 
Recent influenza infection, n (%) 20 (3.2)  25 (1) 
Influenza vaccination in last 6 months, n (%) 184 (27.8)  830 (30) 
Household income, n (%)    
≤$15,000 166 (27.9)  474 (18.5) 
>$15,000 to ≤$30,000 100 (16.8)  455 (17.7) 
>$30,000 to ≤$45,000 53 (8.9)  259 (10.1) 
>$45,000 to ≤$60,000 65 (10.9)  286 (11.1) 
>$60,000  192 (32.3)  975 (38) 
Refused 19 (3.2)  119 (4.6) 
Unknown 66  206 
Insurance type at IPD, n (%)    
Private 288 (44.4)  1449 (52.7) 
Public 344 (53.1)  1227 (44.7) 
Uninsured 15 (2.3)  54 (2.0) 
Other 0  4 (0.1) 
Refused 1 (0.2)  13 (0.5) 
Unknown 13  27 
Race/ethnicity, n (%)    
White, non-Hispanic 259 (39.4)  1368 (49.4) 
Black, non-Hispanic 165 (25.1)  469 (16.9) 
Hispanic 64 (9.7)  191 (6.9) 
Other, non-Hispanic 169 (25.7)  739 (26.7) 
Unknown 4  7 
Primary caregiver education level, n (%)    
Less than high school 78 (12.0)  289 (10.6) 
High school equivalent 134 (20.7)  515 (18.8) 
Some college 193 (29.8)  661 (24.2) 
College degree or more 243 (37.5)  1272 (46.5) 
Unknown 13  37 
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(b) Birth certificate    
Characteristic Enrolled cases 
(n=661) 
Eligible controls 
(n=12,050) 
Enrolled controls 
(n=2,774) 
Maternal race/ethnicity, n (%)    
White, non-Hispanic 268 (46.7) 5055 (43.2) 1488 (54.7) 
Black, non-Hispanic 127 (22.1) 2257 (19.3) 420 (15.4) 
Hispanic 52 (9.1) 1072 (9.2) 186 (6.8) 
Other, non-Hispanic 127 (22.1) 3312 (28.3) 628 (23.1) 
Unknown 87 354 52 
Maternal education level, n (%)    
Less than high school 110 (20.2) 2516 (22.9) 420 (16.8) 
High school equivalent 130 (23.9) 2905 (26.4) 529 (21.2) 
Some college 146 (26.8) 2851 (26.0) 690 (27.6) 
College degree or more 158 (29.0) 2714 (24.7) 857 (34.3) 
Unknown 117 1064 278 
Source of payment for birth, n (%)    
Private 228 (48.2) 4238 (44.9) 1120 (52.9) 
Public/state 223 (47.1) 4707 (49.9) 893 (42.1) 
Uninsured 8 (1.7) 232 (2.5) 41 (1.9) 
Other 14 (3.0) 264 (2.8) 65 (3.1) 
Unknown 188 2609 655 
Adequacy of Prenatal Care Utilization Index, n (%)    
Adequate Plus 183 (34.9) 3377 (31.4) 814 (33.0) 
Adequate 186 (35.5) 4130 (38.4) 972 (39.5) 
Intermediate 67 (12.8) 1360 (12.6) 272 (11.0) 
Inadequate 88 (16.8) 1888 (17.6) 405 (16.4) 
Unknown 137 1295 311 
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Table 6.2. Characteristics of eligible cases and matched controls. Data come from (a) the parent 
interview/medical provider, (b) birth certificates, or (c) American Community Survey. 
(c) American Community Survey    
Characteristic Enrolled cases 
(n=661) 
Eligible controls 
(n=12,050) 
Enrolled controls 
(n=2,774) 
Not successfully geocoded, n (%) 9 (1.4) 179 (1.5) 20 (0.7) 
Median income, n (%)    
≤$15,000 37 (5.7) 796 (6.7) 150 (5.4) 
>$15,000 to ≤$30,000 374 (57.4) 6802 (57.4) 1485 (53.9) 
>$30,000 to ≤$45,000 191 (29.3) 3315 (28) 849 (30.8) 
>$45,000 to ≤$60,000 37 (5.7) 711 (6.0) 204 (7.4) 
>$60,000 13 (2.0) 232 (2.0) 66 (2.4) 
Crowding, median % (IQR)     
0.50 or less occupants per room 68.2 (52.8,77) 67.1 (50.6,77) 69.3 (55,78.1) 
0.51 to 1.00 occupants per room 28.6 (20.9,38.5) 29.7 (22,38.5) 27.5 (19.8,37.4) 
1.01 to 1.50 occupants per room 2.2 (1.1,5.5) 2.2 (1.1,6.6) 2.2 (0,5.5) 
1.51 to 2.00 occupants per room 0 (0,2.2) 0 (0,2.2) 0 (0,2.2) 
2.01 or more occupants per room 0 (0,0) 0 (0,1.1) 0 (0,0) 
Poverty, median % (IQR)     
<100% of poverty level 15.4 (7.7,25.3) 16.5 (8.8,26.4) 13.2 (7.7,24.2) 
100-149% of poverty level 9.9 (5.5,14.3) 9.9 (5.5,15.4) 9.9 (5.5,14.3) 
≥150% of poverty level 73.7 (59.4,85.8) 72.6 (58.3,84.7) 75.9 (61.6,86.9) 
Gini Index*, n (%)    
0.2 to <0.3 17 (2.6) 148 (1.2) 56 (2.0) 
0.3 to <0.4 255 (39.1) 4537 (38.3) 1146 (41.6) 
0.4 to <0.5 325 (49.8) 6092 (51.4) 1324 (48.1) 
0.5 to <0.6 52 (8.0) 1030 (8.7) 219 (8.0) 
0.6 to <0.7 3 (0.5) 48 (0.4) 9 (0.3) 
0.7 to <0.8 0 0 0 
Census tract is > 25% foreign born, n (%) 204 (31.3) 4120 (34.8) 804 (29.2) 
* Measure of income inequality for a geographic area where zero indicates absolute equality and one 
indicates total inequality. 
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Table 6.3. Comparison of results of original model vs. models adjusted for minimally sufficient subsets 
(MSS) for effectiveness against PCV13-type and non-PCV13-type disease. 
 VE (95% CI) PCV13-type 
discordant 
pairsβ 
Absolute % difference 
in VE vs. unadjusted for 
PCV13-types Model± 
PCV13 NVT* 
Original (unadjusted, except for 
matching factors) 
85.1 
(73.8 – 91.9%) 
21.4 
(-18.8 – 47.7%) 
96 Referent 
     
Primary minimally sufficient confounding subset 
MSS1¥: other children in 
household, influenza vaccination 
in the year before culture 
83.5 
(67.3 – 91.6%) 
32.6 
(-12.7 – 59.7%) 
80 -1.6% 
     
Additional minimally sufficient confounding subsets 
MSS2¥: other children in 
household, crowding, influenza 
infection in 30 days before culture 
81.2 
(62.9 – 90.4%) 
35.6 
(-8.3 – 61.7%) 
76 -3.9% 
MSS3¥: caregiver education, 
crowding, influenza infection in 30 
days before culture, prenatal care 
utilization, recent immigrant 
neighborhood 
83.1 
(55.1 – 93.6%) 
39.2 
(-6.5 – 65.3%) 
52 -2.0% 
MSS4¥: caregiver education, 
influenza vaccination in the year 
before culture, prenatal care 
utilization, recent immigrant 
neighborhood 
82.4 
(55.3 – 93.0%) 
35.2 
(-13.6 – 63.0%) 
54 -2.7% 
* PCV13 = 13-valent pneumococcal conjugate vaccine; NVT = non-vaccine types; MSS = Minimally 
Sufficient confounding Subset.  
± All models include adjustment for the matching variables, age and zip code. MSS1 was considered the 
primary subset due to less missing data (most discordant pairs retained). 
β Because this is a conditional (matched) analysis, only matched sets which have discordant vaccination 
status (i.e., vaccinated case/unvaccinated control[s] or unvaccinated case/vaccinated control[s]) 
contribute to the analysis. 
¥ All MSSs included adjustment for: matching factors (age and zip code), asthma, breastfeeding, 
underlying condition, daycare attendance, household income, insurance type at culture, race/ethnicity, 
and smoking exposure. Additional variables included in each subset indicated in table. 
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 GENERALIZABILITY OF VACCINE EFFECTIVENESS ESTIMATES: 
AN ANALYSIS OF CASES INCLUDED IN A POST-LICENSURE EVALUATION OF 13-VALENT 
PNEUMOCOCCAL CONJUGATE VACCINE 
Overview 
External validity, or generalizability, is the measure of how well results from a study pertain to 
individuals in the target population. We assessed generalizability, with respect to socioeconomic status, 
of estimates from a matched case-control study of 13-valent pneumococcal conjugate vaccine 
effectiveness for prevention of invasive pneumococcal disease in children in the US. Cases were 
identified from active surveillance and controls were age and zip code-matched. We enrolled 54.6% of 
eligible cases and found a trend toward enrolled cases being more affluent than unenrolled cases. 
Enrolled cases were slightly more likely to have private insurance at birth (p=0.08) and have mothers 
with at least some college education (p<0.01). Enrolled cases also tended to come from more affluent 
census tracts. Despite these differences, our best predictive model for enrollment yielded a concordance 
statistic of only 0.703, indicating mediocre predictive value. Variables retained in the final model were 
assessed for effect measure modification and none were found to be significant modifiers of vaccine 
effectiveness. We conclude that, although enrolled cases are somewhat more affluent than unenrolled 
cases, our estimates are externally valid with respect to socioeconomic status. Our analysis provides 
evidence that this study design can yield valid estimates and the assessing generalizability of 
observational data is feasible, even when unenrolled individuals cannot be contacted. 
Introduction 
External validity, or generalizability, is the measure of how well results from a study pertain to 
individuals in the target population.116-118 Study results may fail to generalize to a target population 
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under several circumstances.6,116  A key reason that studies fail to be generalizable is when both of the 
following criteria are met: (a) selection/enrollment into the study is differential with respect to variable 
X (i.e., the study population is not representative of the source population with respect to variable X, 
which is usually a potential confounder), and (b) variable X modifies the exposure/outcome relationship 
under study.6,116 
Increased external validity can be a major benefit of observational studies as compared to 
randomized controlled trials (RCTs).6,89,91,92,117,118,137,138 Unlike in RCTs, where strict exclusion criteria are 
often used, observational studies usually enroll a broader subset of the population.118 This may be 
especially true in case-control studies, in which researchers commonly attempt to enroll every case of 
disease in a given surveillance population (e.g., geographic area or hospital system).139 With the 
assumption that the study source population (in this case the surveillance area) does not vary in a 
meaningful way from the target population (e.g., an entire country), then results from observational 
studies may be more generalizable than those from RCTs.139  
Unfortunately, due to issues related to tracking, contacting, and enrolling participants, and in 
some cases obtaining needed biological samples from participants, generalizability in observational 
studies may not be achieved, even when a priori exclusion criteria are minimal. In particular, the study 
population may differ from the source population by socioeconomic status (SES), which is frequently 
associated with characteristics that may affect enrollment probability.120 For example, less affluent 
individuals may lack a landline or frequently switch cell phone numbers, making them harder to reach; 
they may hold multiple jobs or have long commutes, making them less likely to answer their phone; they 
may have diminished use of or trust in the medical system, making them less likely to agree to 
enrollment; they may seek care at underfunded (e.g., public) hospitals which lack the resources to enroll 
participants and preserve specimens.5,9,99,132,140,141 On the other hand, lower SES individuals may be more 
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likely to join a study that provides a monetary incentive for participating versus those of higher SES for 
which the monetary incentive is lower. 
While not always a problem, lack of representativeness by SES may reduce external validity if 
SES modifies the effect of the exposure/outcome relation under study.100,107,142 One way to explore 
generalizability as it relates to SES is to evaluate differences in SES indicators between those selected 
into a study and those who were eligible, but not selected. Although some individual SES constructs, 
such as use of or trust in the medical system, may not be measured accurately, others, such as 
educational attainment, are more readily available. Additionally, other characteristics, such as recent 
immigration, insurance status, and utilization of prenatal care, can serve as proxies for harder to 
measure SES constructs, providing some context for the demographic characteristics of the underlying 
source population and their participant population.  
Many studies are not able to access extensive SES information for individuals who are not 
enrolled. We present an analysis of the external validity of estimates from a study with access to 
relatively detailed information on unenrolled cases, providing a rare opportunity to assess differences in 
key SES variables between enrolled and unenrolled cases and, for variables with substantial differences, 
assessed effect measure modification (EMM), using data from a large matched case-control study of 13-
valent pneumococcal conjugate vaccine (PCV13). 
Methods 
Parent study and study population 
PCV13 was introduced in the US in 2010 as part of the routine childhood immunization 
schedule.25 Licensure was largely based on immunogenicity and safety data, making a post-licensure 
evaluation the best opportunity to measure vaccine effectiveness.25,119 The primary aim of the parent 
study was to assess the effectiveness of 1 or more doses of PCV13 in preventing invasive pneumococcal 
disease (IPD) caused by one of the 13 serotypes included in the vaccine.119 Cases of IPD were identified 
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through Active Bacterial Core surveillance (ABCs), part of the Centers for Disease Control and 
Prevention’s (CDC) Emerging Infections Program, or through one of three additional surveillance sites 
with similar case identification methods.105,119 The source population consisted of IPD cases in children 
aged 2-59 months with culture dates between May 1, 2010 and May 31, 2014. Only children with a 
pneumococcal serotype available were eligible for enrollment. Additionally, children were deemed 
ineligible if the IPD episode was recurrent or if they were living in a long-term care facility at the time of 
culture.  
In addition to the exclusion criteria for the parent study, we excluded cases from two ABCs sites, 
Colorado and Maryland, because the necessary SES data were not available from those sites. 
In the current study, almost 45% of cases were not enrolled because they lacked a specimen for 
serotyping, could not be located, or refused enrollment, leading to concerns about representativeness 
with respect to SES (Table 7.1). Further, past studies of IPD and pneumococcal vaccines have provided 
some evidence for differential risk of IPD at different levels of individual SES, potentially due to the 
association of lower SES with IPD risk factors (e.g., existing chronic or immunocompromising conditions, 
smoking exposure, household crowding). 
Enrollment procedures 
Enrollment procedures have been previously published.119 Briefly, once a case was identified via 
routine surveillance, study staff attempted to locate a correct phone number for the case. If a case was 
successfully located, staff began the enrollment process, which included attempting to interview a 
parent/guardian to gain consent and to ascertain medical history, IPD risk factors (e.g., smoking 
exposure, household crowding), and contact information for vaccine providers. A $20 gift card was 
offered as an incentive. Study staff then contacted vaccine providers to ascertain vaccine and medical 
histories. Staff also reviewed any available vaccine histories through state or city immunization 
information systems. If a parent/guardian could not be contacted or refused enrollment, if a vaccine 
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history could not be obtained, or if the parent/guardian did not speak English or Spanish, the case was 
excluded. Both the parent study and the current analysis were approved by institutional review boards 
at CDC and surveillance sites. The current analysis was also approved by the IRB of the University of 
North Carolina – Chapel Hill.   
Lists of eligible controls were obtained from local birth registries for children born in the same 
zip code in which the case resided when diagnosed with IPD and born within 14 days of the case. 
Controls were called in order, beginning with those closest in age to the case, until 4 controls were 
enrolled for every case. Enrollment proceeded for controls in an identical manner to cases. Additionally, 
controls were excluded if they had moved out of the surveillance area by the case’s culture date, they 
had been previously approached for enrollment, they were the sibling of a previously enrolled child, 
their birth mother no longer had custody, or if they had died for any reason. Detailed information on 
eligible and enrolled controls has been previously published.143 
Covariate assessment 
Every IPD case identified through ABCs has a standard case report form completed by 
surveillance staff.108 We included the following variables from the case report form: hospitalization 
status, length of hospitalization and ICU admission (if hospitalized), outcome (survived/died), presence 
of an underlying condition which is a known risk factor for IPD, and insurance status at IPD culture.25,108 
Hospitalization and intensive care unit (ICU) admission were combined into a three-level severity index, 
with a child who was not hospitalized being the least severe, followed by a hospitalized child who was 
not admitted to the ICU, and then a child admitted to the ICU. 
Individual-level SES indicators 
For cases and controls, study staff obtained variables from the US standard birth certificate.144 
Variables collected included: mother’s race, ethnicity, and education, source of payment for the birth, 
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and timing/initiation of prenatal care and gestational age, which were used to calculate the Adequacy of 
Prenatal Care Utilization (APNCU) Index.110,111 The APNCU is a four-category variable which summarizes 
both how early in the pregnancy a woman initiated prenatal care and how many total prenatal care 
visits the woman received compared to how many are recommended by the American College of 
Obstetrics and Gynecology for a pregnancy of a given length.110,111 Insurance status and APNCU Index 
were collected as measures of the individual’s access and use of the medical system.120  
Neighborhood-level SES indicators 
All enrolled and unenrolled children were geocoded by surveillance site personnel, using a 
standard geocoding protocol (available from the authors upon request). For children whose locations 
could not be confirmed, surveillance staff geocoded the most recent known address (from the birth 
certificate, state or city immunization registry, or medical chart). Census tract data were merged with 
the 2013 5-year estimates from the American Community Survey (ACS), an annual survey conducted by 
the US Census Bureau, which includes demographic and SES indicators, such as median household 
income, employment rates, and distribution of crowding. These census tract-level estimates can be a 
useful tool for understanding the context in which a child lives by complementing individual-level SES 
indicators.123,128 
Comparison groups 
It is important to note that in matched case-control studies, controls need not be representative 
of the source population with respect to the matching factor(s). In fact, if matching is done correctly, 
controls should resemble enrolled cases on the matching factor. This analysis, therefore, focuses on 
representativeness of enrolled cases with respect to eligible cases and leaves questions concerning 
controls for other analyses.143  
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Statistical methods 
Exploratory analyses looked at univariate differences in individual-level characteristics and ACS 
variables between enrolled and unenrolled cases. We also used the ACS variables to calculate a 
composite index of SES, based on the Socioeconomic Position Index (SEP Index) created by Krieger et al. 
for the Public Health Disparities Geocoding Project.24 The SEP Index measures the major SES constructs 
of wealth, education, and occupation at the neighborhood level. Specifically, it includes: working class, 
unemployment, poverty, education, home prices, and median family income (with home prices and 
median income reversed, so a higher SEP score indicates lower SES).145 P-values were calculated for 
continuous and categorical predictors via two-sided Wilcoxon rank sum test and Fisher’s exact test, 
respectively. 
Because we had access to many SES-related variables through the case report form, birth 
certificates, and ACS, it was not practical to assess every variable for effect measure modification 
(EMM). Instead, we chose variables to assess for EMM in two ways. First, we decided a priori to assess 
as modifiers the SEP Index and the following individual-level variables which had p-values <0.2 in the 
exploratory analyses for differences between enrolled and unenrolled: maternal education, insurance 
status at birth, and APNCU. Second, to ensure we did not miss any variables for the EMM assessment 
that may be strong modifiers and related to representativeness, we used predictive modeling to select 
additional ACS variables to assess for EMM. Many of the available ACS variables measured similar 
metrics (both to other ACS variables and to the individual variables); therefore, we fit a series of models 
to narrow the selection. All models fit were logistic regression, using backward selection and retaining 
variables with a p-value of <0.2.  
We first fit a single predictive model including all individual-level variables (i.e., case report form 
and birth certificate variables), requiring the model to retain the following case report form variables: 
severity, outcome, underlying condition status, child’s race/ethnicity, and insurance status at IPD. This 
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model also included interaction terms between child’s race/ethnicity and maternal education and 
between child’s race/ethnicity and APNCU. We then divided the ACS variables into four categories – 
demographics, wealth, work, and household characteristics – for inclusion in separate models to reduce 
the number of ACS variables used. Four models were run, including all individual-level variables retained 
from the first model and each category of the ACS variables. Lastly, we fit the final predictive model, 
which included all the individual-level variables and interaction terms (regardless of whether they were 
retained in the first model) and any variables retained in the ACS models. As with the first model, we 
required the model to retain the case report form variables. 
 Any variables included in the final model predicting enrollment were assessed as potential 
modifiers, in addition to the SEP Index and individual-level variables chosen a priori. All the individual-
level variables were already categorical. We did not include variables (i.e., severity of IPD, outcome 
status) that are not applicable to controls. Additionally, variables obtained from the case report form for 
cases (child’s race/ethnicity, underlying condition status, and insurance status at IPD) were not available 
for controls (since no case report form is completed for controls); however, these variables were 
collected as part of the parent interview/provider follow-up for enrolled children and could therefore be 
assessed for EMM. The ACS variables were continuous, so we dichotomized them at the median for the 
EMM analysis. To assess variables as modifiers, we fit conditional logistic regression models for each 
variable with IPD caused by one of the 13 serotypes included in the vaccine as the outcome, receipt of 
one or more doses of PCV13 as the exposure, and an interaction term between each variable of 
interested and PCV13 receipt.119 Because power to assess interaction terms is reduced, we used a p-
value <0.2 as our cutoff for the likelihood ratio chi-square value for the interaction term and then did a 
Bonferroni adjustment by the total number of variables assessed for EMM to account for multiple 
comparisons. Therefore, α<0.015 for the likelihood ratio test was considered an indication of 
modification and cause for concern about generalizability. 
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Results 
Enrollment 
The annual population of children under age five in the catchment area for the parent study 
included approximately 4.7 million children, which was reduced to 4.2 million with the exclusion of sites 
that could not obtain the necessary variables for purposes of this analysis. We identified 1,214 cases of 
IPD in children in the catchment area used for this analysis. Three children were initially miss-
categorized as ineligible by surveillance personnel and enrollment was not attempted, leaving 1,211 
cases in our analysis, 661 (54.6%) of whom were enrolled (Table 7.1). Of the 550 cases not enrolled, 194 
(35.3%) could not be located/contacted, 177 (32.2%) refused, and 158 (28.7%) did not have a 
pneumococcal isolate available for serotyping. The remaining 21 children were not enrolled for other 
reasons.  
Differences between enrolled and unenrolled cases 
Enrolled and unenrolled cases were of similar age (median age 21-22 months) and race/ethnicity 
(42%-43% white, non-Hispanic, p=0.41; Table 7.2a). Enrolled children were slightly more likely to have 
private insurance coverage at the time of IPD culture (49.9% vs. 47.7%), to be hospitalized (68.8% vs. 
66.4%) and, if hospitalized, more likely to have been admitted to the ICU (31.9% vs. 29.0%), although 
none of these differences were statistically significant. Enrolled children were slightly more likely to 
survive their illness (98.8% vs. 97.0%, p=0.04), and slightly less likely to have an underlying chronic or 
immunocompromising condition, although differences in underlying conditions were not statistically 
significant. 
As with the children themselves, mothers of enrolled and unenrolled children had a similar 
racial/ethnic distribution (Table 7.2b). Differences in insurance status at birth were more pronounced 
than those at culture, with 48.2% of enrolled children having private insurance at birth compared with 
only 39.8% of unenrolled children (p=0.08). Maternal education was also somewhat different between 
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the two groups, with 44.1% of mothers of enrolled children having no college education compared to 
53.9% of mothers of unenrolled children (p<0.01). Mothers of enrolled and unenrolled children had 
relatively similar APNCU Index scores (p=0.16); however, when broken into its individual components, 
enrolled children had earlier prenatal care initiation (p=0.01). 
 Univariate differences between enrolled and unenrolled cases in ACS variables retained in the 
predictive model are in Table 7.2c. The SEP Index was similar in enrolled and unenrolled cases (p=0.07). 
A number of characteristics differed between the two groups, including proportion with an income 
above $60,000, proportion disabled, and proportion of households occupied (p<0.01 for all). 
Enrollment prediction model 
Full results of the predictive models are in Table 7.3. In the individual-level model, three 
variables – maternal education, APNCU, and the interaction between race/ethnicity and maternal 
education – were retained in addition to the five variables that we required. The model yielded a 
concordance (c-) statistic of 0.639, indicating only marginal predictive ability (0.5 is equal to a coin 
flip).146 Retaining these eight variables and adding demographic, wealth, work, and household variables 
from the ACS yielded similarly low c-statistics of 0.632, 0.652, 0.643, and 0.655, respectively. The final 
predictive model included IPD severity, outcome, underlying condition status, child’s race/ethnicity, 
insurance status at IPD, maternal education, APNCU, race/ethnicity and maternal education interaction, 
as well as the following census tract variables: percent of tract of white race, earning <$30,000, earning 
≥$60,000, disabled, working class, occupied households, and mean hours worked (Table 7.4). This model 
had a concordance statistic of 0.703, indicating only slightly better predictive ability than the single ACS 
category models.  
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Effect measure modification 
None of the individual-level variables retained in the prediction model were found to be 
significant modifiers of the effect of PCV13 receipt on IPD caused by one of the 13 serotypes in the 
vaccine (Figure 7.1a). Likewise, none of the ACS variables (including SEP Index) assessed as modifiers had 
a p-value<0.015 for the likelihood ratio test (Figure 7.1b).  
Discussion 
We assessed the external validity of vaccine effectiveness estimates from a post-licensure 
evaluation of PCV13 in children in the US. Despite a small trend toward enrolled cases being more 
affluent than unenrolled cases, the differences were minimal and most did not meet a priori definitions 
of significance. Additionally, we did not find EMM of the vaccine effectiveness by any of SES variables 
and therefore conclude that lack of generalizability to the broader source population is of minimal 
concern in the current study. Our results provide some evidence that study designs based on 
population-based surveillance systems can be generalizable – in particular, when researchers conduct 
extensive investigations into case contact information and provide incentives (in our case, a $20 gift 
card) to encourage enrollment. 
  Generalizability can be a major benefit of observational vaccine studies over RCTs92,147; however, 
it is rare for reports on either study type to provide extensive information on how their study population 
differs from their source or target population.116,148 Our study used a novel approach to assessing 
generalizability with respect to SES, assessing a mix of variables chosen a priori and through predictive 
modeling. We had access to more detailed information on unenrolled cases than is typical; however, the 
data we assessed were collected without patient contact and therefore could be gathered more 
routinely in observational studies. Our analysis shows that assessing and reporting on generalizability 
may be feasible even when it is not possible to interview unenrolled cases. 
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 Post-licensure vaccine effectiveness studies are common tools to assess the “real world” 
effectiveness of vaccines and, as with similar studies, cases were identified from a disease surveillance 
system.41,42,46,105 Generalizability of results with respect to SES from vaccine studies is an important 
component of assessing the overall quality of a study, as well as the utility of results beyond the study 
population. Thus, although we found little cause for concern in the current analysis, this conclusion may 
not be applicable for vaccines for diseases, such as rotavirus, which are spread differently and therefore 
may have different risk factors and potential modifiers. Likewise, if case identification or enrollment 
methods are different, representativeness to the source population could be lacking. Since SES has been 
identified as a significant risk factor for many vaccine preventable diseases, other post-licensure vaccine 
studies may find more substantial cause for concern. However, careful selection of case and control 
populations, regardless of the disease under study, can yield results, such as these, which are 
generalizable to the underlying source population. 
Our study had some limitations. We did not have access to variables collected during the parent 
interview (e.g., household income) for unenrolled cases and so could not explore differences between 
enrolled and unenrolled cases for these variables. We may have also lacked sufficient power to identify 
EMM in our study. For example, the confidence limits for vaccine effectiveness amongst those without 
insurance were extremely wide. Likewise, a vaccine effectiveness study of the 7-valent pneumococcal 
conjugate vaccine (a more limited valency, but otherwise identical, vaccine) in a similar population to 
the current analysis found clear evidence of EMM by underlying condition status.42 We did not identify 
EMM, but only had two matched sets with underlying conditions and discordant vaccination status 
(required to contribute to a conditional analysis) in our study. Additionally, we were not able to compare 
cases eligible for our study (i.e., the source population) to cases throughout the US (i.e., the target 
population) because active, population-based surveillance for IPD does not exist nationwide.  
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 We identified minimal external validity concerns in a PCV13 vaccine effectiveness study in 
children in the US. Nevertheless, future vaccine effectiveness studies should take care to enroll as broad 
a subset of cases as possible, especially focusing on children from lower SES areas. Additionally, every 
effort should be made to gather at least basic SES information so that study populations can be 
compared to source populations and estimates can be understood in context. 
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Table 7.1. Enrollment numbers, reasons for non-enrollment, and geocoding status for cases 
Enrollment status Cases, n (%) Could not be geocoded, n (%) 
Annual surveillance population <5 years of age* 4,249,724 N/A 
IPD cases identified 1,211± 21 (1.8) 
Enrolled 661 (54.6) 9 (1.4) 
Not enrolled 550 (45.4) 12 (2.2) 
Could not locate/contact 194 (35.3) 4 (2.1) 
Refused 177 (32.2) 5 (2.8) 
No serotype available 158 (28.7) 2 (1.3) 
Recurrent 11 (2.0) 1 (9.1) 
Vaccine history not available 6 (1.1) 0 
Resident of long-term care facility 4 (0.7) 0 
* Average population <5 years of age in the catchment area.  
± Excludes 3 children originally miss-classified as ineligible and excluded from this analysis. 
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Table 7.2. Characteristics of eligible cases by enrollment status. (a) ABCs case report form (cases only); 
(b) birth certificate variables; (c) American Community Survey. 
(a) ABCs case report form 
Characteristic Enrolled  
(n=661) 
Not enrolled 
(n=550) 
p-value* 
Median age, median months (IQR) 21 (11-37) 22 (12-37) 0.27 
Child’s race    
White, non-Hispanic 262 (42.2) 217 (43.1) 0.41 
Black, non-Hispanic 157 (25.3) 139 (27.6)  
Other, non-Hispanic 64 (10.3) 55 (10.9)  
Hispanic 138 (22.2) 92 (18.3)  
Unknown 40 47  
Insurance status at IPD    
Private 207 (49.9) 205 (47.7) 0.83 
Public 254 (47.0) 208 (48.4)  
Military 2 (0.4) 2 (0.5)  
Uninsured 15 (2.8) 15 (3.5)  
Other/unknown 120 120  
Hospitalized 454 (68.8) 354 (66.4) 0.38 
Median length of stay in days, (IQR) 5 (3-10) 5 (2-10) 0.65 
ICU 124 (31.9) 89 (29.0) 0.46 
Survived 648 (98.8) 511 (97.0) 0.04 
Chronic condition 9 (1.4) 5 (0.9) 0.59 
Immunocompromising condition 64 (9.7) 64 (11.6) 0.30 
* P-value is from Wilcoxon rank sum test for continuous variables and Fisher’s exact test for categorical 
variables. 
IQR=Interquartile range; IPD=Invasive pneumococcal disease; ABCs=Active Bacterial Core surveillance; 
ICU=Intensive care unit 
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(b) Birth certificates 
Characteristic Enrolled 
(n=661) 
Not enrolled 
(n=550) 
p-value* 
Maternal race/ethnicity, n (%)    
White, non-Hispanic 268 (46.7) 206 (44.8) 0.22 
Black, non-Hispanic 127 (22.1) 127 (27.6)  
Hispanic 52 (9.1) 36 (7.8)  
Other, non-Hispanic 127 (22.1) 91 (19.8)  
Unknown 87 90  
Maternal education level, n (%)    
Less than high school 110 (20.2) 99 (22.7) <0.01 
High school equivalent 130 (23.9) 136 (31.2)  
Some college 146 (26.8) 115 (26.4)  
College degree or more 158 (29.0) 86 (19.7)  
Unknown 117 114  
Source of payment for birth, n (%)    
Private 228 (48.2) 151 (39.8) 0.08 
Public/state 223 (47.2) 209 (55.2)  
Uninsured 8 (1.7) 9 (2.4)  
Other 14 (3.0) 10 (2.6)  
Unknown 188 171  
Adequacy of Prenatal Care Utilization, n (%)    
Adequate Plus 183 (34.9) 135 (32.8) 0.16 
Adequate 186 (35.5) 157 (38.1)  
Intermediate 67 (12.8) 37 (9.0)  
Inadequate 88 (16.8) 83 (20.2)  
Unknown 137 138  
Gestational age, median weeks (IQR)± 39 (38-40) 39 (38-40) 0.57 
Prenatal care initiation, median month (IQR) ± 2 (2-3) 3 (2-4) 0.01 
Total prenatal care visits, median (IQR) ± 12 (10-16) 12 (10-18) 0.94 
* P-value is from Wilcoxon rank sum test for continuous variables and Fisher’s exact test for categorical 
variables. 
± Included in calculation of Adequacy of Prenatal Care Utilization Index.110,111 
IQR=Interquartile range 
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(c) American Community Survey. Unless otherwise noted, all measurements are the median percent 
(IQR) by census tract. 
Characteristic Enrolled 
(n=661) 
Not enrolled 
(n=550) 
p-value 
(univariate)* 
p-value 
(multivariable model) 
Successfully geocoded, n (%) 652 (98.6) 538 (97.8) 0.28 N/A 
White race 56.1 (17.6, 81.9) 58.9 (19.8, 83.9) 0.26 <0.01 
Household income <$30,000 28.1 (17.3, 38.5) 29.9 (18.9, 42.1) 0.03 <0.01 
Household income ≥$60,000 41.1 (29.4, 57.8) 38.2 (25.1, 53.8) <0.01 <0.01 
Mean hours worked (annually) 38.1 (36.8, 39.3) 38.0 (36.7, 39.2) 0.39 0.05 
Disabled workers 10.1 (7.5, 13.5) 11.2 (8.2, 16.0) <0.01 <0.01 
Working class 60.3 (52.6, 69.8) 62.3 (52.5, 69.8) 0.36 <0.01 
Occupied houses 92.4 (88.1 ,95.8) 91.3 (86.4, 94.7) <0.01 0.07 
SEP Index±, median (IQR) 1.5 (-1.4, 4.5) 2.1 (-0.8, 4.9) 0.07 N/A 
* P-value is from Wilcoxon rank sum test for continuous variables and Fisher’s exact test for categorical 
variables. 
± Socioeconomic position index. Higher value indicates higher level of deprivation.24 IQR=Interquartile 
range
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Table 7.3. Prediction models for case enrollment 
 
  
Model # of variables in model AIC C-statistic 
Start After selection   
Individual-level 11 7 (IPD severity, outcome, underlying condition status, race/ethnicity, insurance at IPD, 
maternal education,  race/ethnicity*maternal education) 
717.840 0.639 
ACS: demographics 26 9 (individual-level from above + percent: white race, speaks English) 927.995 0.632 
ACS: wealth 18 11 (individual-level from above + percent: living abroad 1 year ago, earning <$30,000, 
earning ≥$60,000, per capita income) 
927.838 0.652 
ACS: work 16 10 (individual-level from above + percent: mean hours worked, disabled, working class) 932.599 0.643 
ACS: household  30 14 (individual-level from above + percent: owner-occupied housing units, households 
with one resident, households without children <18 years, crowded households, 
households with plumbing, households with kitchens, occupied housing units) 
896.747 0.655 
Final (all individual-
level, plus retained 
ACS variables) 
27 15 (individual-level from above + APNCU Index, percent: white race, earning <$30,000, 
earning ≥$60,000, disabled, working class, occupied houses, mean hours worked) 
690.606 0.703 
ACS=American Community Survey; IPD=Invasive pneumococcal disease; APNCU=Adequacy of Prenatal Care Utilization Index; AIC=Akaike 
information criterion 
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Table 7.4. Operational definitions of ACS variables included in final prediction model 
Category Variable name Variable description ACS Table 
Number 
Cut point (median) for 
EMM analysis 
Demographic White race Percent of individuals identifying as white, non-Hispanic B03002 48.3% 
Wealth Household income 
<$30,000 
Household income in the past 12 months (in 2013 inflation-
adjusted dollars) 
B19001 28.0% 
 Household income 
≥$60,000 
Household income in the past 12 months (in 2013 inflation-
adjusted dollars) 
B19001 40.4% 
Work Working class Percent of individuals reporting jobs in sales, service (except 
protective), production, transportation, and material moving, 
natural resources, construction and maintenance 
C24010 61.4% 
 Disabled Percent of individuals with a disability B18135 10.3% 
 Mean usual hours 
worked 
Mean number of hours worked annually B23020 37.9 hours 
Household Units occupied Percent of occupied housing units B25002 92.3% 
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(a) Individual-level variables  
  
 
Figure 7.1. Vaccine effectiveness (and 80% CIs) for characteristics retained in the final predictive model, stratified as indicated. (a) Individual 
variables; (b) ACS variables, divided at median. 
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(b) ACS variables 
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 DISCUSSION 
Overview 
In the years following the introduction of PCV7, the burden of disease caused by S. pneumoniae 
in the US was reduced, but remained substantial.66,67 In 2004, four years after PCV7 was introduced, 
direct medical costs of disease (including invasive and noninvasive disease) were estimated to be 
approximately $3.5 billion, including over one million episodes in children under five years of age and 
1.1 million courses of antibiotics.149 Costs likely changed little in the intervening years before PCV13 
introduction, due to replacement disease and increasing medical costs in general.66,149 The introduction 
of PCV13 in 2010 thus represented a significant opportunity to impact rates of disease, antibiotic usage 
(and thus, resistance), and healthcare costs. However, given remaining racial disparities in disease 
burden after PCV7 introduction, concerns about differential impact by race and/or socioeconomic status 
were raised and when CDC began an evaluation of the effectiveness of PCV13 in 2010, a secondary 
objective included evaluating the effectiveness in white vs. black children.73,79,119   
Early in the enrollment process for the PCV13 VE study, it became apparent that study sites 
were having a more difficult time locating and enrolling children than had been the case during the PCV7 
VE study a decade before. Site surveillance personnel raised concerns about the increased use of cell 
phones, higher proportions of recent immigrant families who were more transient and harder to locate, 
and recognized that there appeared to have been an increase in the number of parents/guardians of 
eligible children who did not speak English or Spanish and therefore could not be enrolled. Minnesota 
and New York City were particularly concerned about non-English/Spanish speaking populations, while 
Los Angeles County found it difficult to even contact parents/guardians of many eligible children 
(personal communications from C. Holtzman, J. Rosen, T. Motala, and R. Guevera).  
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In the interest of exploring how these issues might impact VE estimates, and adjusting our 
estimates if necessary, we began collecting additional data – geocodes and birth certificate variables – 
on eligible children. The overarching goal was to assess the validity of estimates from the current study 
with respect to SES and to make recommendations for changes in the study design for future VE studies. 
We hypothesized that 1) controls would be more affluent than cases, and 2) that enrolled children 
(cases and controls) would be more affluent than unenrolled children. The most likely change to the 
study design would be tighter matching criteria (either excluding adjacent zip codes or matching on 
census tract instead of zip code), although more drastic changes, such as matching via a pediatrician’s 
office or using birth certificate variables to match, were also discussed. Simultaneously, CDC was 
drafting the protocol for an adult PCV13 VE study, and it was hoped that findings from the pediatric 
study could help inform methods for the adult study. 
Summary of findings 
 In general, our hypotheses that controls would be more affluent than cases and that enrolled 
children would be more affluent than unenrolled children were confirmed in our univariate analyses. 
Controls tended to have better educated mothers and primary caregivers, live in households with higher 
family incomes, and were more likely to have private health insurance (both at birth and at time of IPD 
culture). Enrolled children (cases and controls) were similarly more affluent than their unenrolled 
counterparts (although family income for unenrolled children was not available). 
 Differences were less obvious at the census tract level, as census tracts are neighborhood 
measures that may or may not apply directly to individuals. There was, however, a slight trend toward 
controls coming from less crowded, wealthier census tracts with a lower percentage of recent 
immigrants compared to cases. Likewise, enrolled controls were slightly better off than eligible controls. 
No clear trend was seen in differences between enrolled and unenrolled cases. 
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Aim 1 
 While our general hypothesis was that controls would be less affluent than cases, we were 
interested in deconstructing the factors that go into a control sample in a matched study. Specifically, 
we wanted to separate the effects of zip code matching from those of selection and determine both if 
zip code matching worked in theory and if the composition of our actual control sample was altered by 
selection. While the combined answers to these questions dictate whether we should be concerned 
about internal validity, each question individually determines if changes should be made to the study 
design for future vaccine effectiveness studies.  
 The first part of this analysis involved a comparison between enrolled cases and eligible 
controls, with the aim of determining whether zip code matching worked to control for SES, in the 
absence of problems locating, contacting, and enrolling controls. Specifically, if zip code matching 
worked, we would expect eligible cases to look similar to enrolled cases with respect to characteristics, 
such as income, education, and insurance status, which measure SES. Using the birth certificate and ACS 
variables, we found that eligible controls were actually slightly less affluent that enrolled cases, as 
measured by maternal education and insurance status at birth.  
 The second part of the analysis compared enrolled cases to enrolled controls, with the goal of 
determining whether selection into the study resulted in a control group that was more or less similar to 
enrolled cases than the eligible controls. We found enrolled controls to be slightly more affluent than 
enrolled cases. 
 When all confounders from our minimally sufficient subsets were included in models, we did not 
find substantial cause for concern about reduced internal validity. Interestingly, while there were 
differences between our enrolled cases and controls, they did not have a meaningful change in our 
overall estimate. One possible explanation for the lack of effect on the overall estimate is that, while SES 
is related to IPD risk, it may be less related to vaccination than has historically been the case. The 
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passage and implementation of the Vaccines for Children (VFC) program has no doubt reduced 
disparities in vaccination coverage. Additionally, since PCV13 simply replaced PCV7 in the immunization 
schedule (rather than adding an additional vaccine to the schedule), acceptance may have been higher 
among parents, further reducing disparities.  
Aim 2 
 As with Aim 1, differences between groups were seen in individual variables, but did not result 
in significant findings for multivariable models. In the case of Aim 2, despite differences between 
enrolled and unenrolled children, our predictive models were mediocre, implying that we could not fully 
predict enrollment based on a child’s SES. This is an important finding, which should allay some concerns 
about selection bias and reinforce the notion that generalizability can be a major strength of 
observation studies. 
Strengths 
This study was the first to evaluate concerns about internal and external validity due to SES in a 
pediatric case-control vaccine effectiveness study in the US. Few studies of any kind have such 
comprehensive information on those cases and controls who are eligible for the study, but not enrolled, 
and we were thus be in a unique situation to assess the potential for bias. Further, with the exception of 
a handful of variables collected via parent interview, the majority of our SES indicators were collected 
without patient contact, demonstrating that routine assessment of validity in observational studies need 
not require exhaustive follow-up beyond study enrollment procedures. Additionally, strong existing 
disease surveillance and a catchment area of greater than 4 million children meant relatively high 
numbers of cases. Finally, as neighborhood matching and enrollment via telephone are common design 
components in observational studies, our results may inform future studies, both of vaccine 
effectiveness and other disease endpoints. 
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Limitations 
ABCs surveillance sites are not randomly chosen and our results may therefore not be 
generalizable to the entire US population. Thus, we focused our generalizability analyses on whether our 
enrolled cases represented eligible cases within ABCs, rather than all cases within the US. Because 
active, population-based surveillance for IPD does not exist throughout the US, we could not address 
generalizability of cases within ABCs with respect to cases throughout the US. However, because of the 
wide geographic spread of ABCs, and the clear geographic boundaries of the catchment area, in the 
future we will be able to explore differences in our catchment area population as compared to the rest 
of the country. These analyses are ongoing within CDC. 
Some misclassification of location was possible, due to incorrectly reported addresses and/or 
issues with geocoding procedures or software. This misclassification should be minor as sites followed 
standard geocoding procedures, including hand-checking any addresses that software initially failed to 
geocode. Further, small issues with specific addresses (e.g., typos in the street number) are unlikely to 
change the census tract, mitigating problems arising from errors in data entry. Further, because we 
collected both address at time of birth and IPD culture, if one address for a child was invalid (e.g., a P.O. 
Box), we frequently had a second address that was valid. 
 Finally, although the variables available in this study are likely better proxies for individual-level 
SES than zip code, they are unlikely to be perfect. For example, we did not have access to the actual 
income level of families not enrolled in the study, an important measure of SES; however, since perfect 
SES measures are unlikely to be available in most large studies, it is of substantial interest to better 
understand and utilize the available measures, such as those used in our study. 
Future directions 
 As previously discussed, work is ongoing to explore the representativeness of the ABCs 
catchment area with respect to the entire US. Those findings will help us understand whether results 
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from both routine surveillance (e.g., disease trends) and special studies (e.g., vaccine effectiveness, risk 
factor analyses, etc.) are applicable to the entire US population. 
 The adult PCV13 vaccine effectiveness study, which is just beginning enrollment at the time of 
this writing (winter 2015/2016), will include, for the first time in an ABCs special study, routine, 
prospective geocoding of all eligible cases and controls, regardless of enrollment status. Identification of 
individual-level variables for eligible cases and controls (adults 65 years and older) was more difficult 
than for children, given the lack of a universal registry for elderly adults; however, some data may be 
available via Medicare enrollment databases from the Centers for Medicare and Medicaid Services. 
Discussions of this possibility are ongoing. 
Conclusions 
 Our results provide assurance that previously published vaccine effectiveness estimates are 
both internally and externally valid. Further, we did not identify substantial need to change the basic 
case/control identification and enrollment methods in future studies. Rather, we showed that 
observational studies can (and should) evaluate validity in quantitative, rather than qualitative ways. 
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APPENDIX 1: PNEUMOCOCCAL VACCINES USED IN THE US SINCE 2000 
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* Wyeth Lederle was purchased by Pfizer in 2009. 
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APPENDIX 2: 2014 ABCS CASE REPORT FORM 
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APPENDIX 3: MEDICAL AND VACCINE HISTORY FORM 
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